{
    "nodes": [
        {
            "ix": "5-758_v2_0",
            "content": "Use of cidofovir in pediatric patients with adenovirus infection",
            "ntype": "article-title",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_1",
            "content": "Abstract",
            "ntype": "abstract",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_2",
            "content": "Background : Adenoviruses contribute to morbidity and mortality among immunocompromised pediatric patients including stem cell and solid organ transplant recipients. Cidofovir (CDV), an antiviral compound approved by the FDA in 1996, is used for treatment of adenoviral (ADV) infections in immunocompromised patients despite concern of potential nephrotoxicity.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_3",
            "content": "Methods : We conducted a retrospective 5-year review at Boston Children\u2019s Hospital of 16 patients (mean age = 6.5 years) receiving 19 courses of CDV. During therapy all pertinent data elements were reviewed to characterize potential response to therapy and incidence of renal dysfunction.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_4",
            "content": "Results: Of the 19 CDV courses prescribed, 16 courses (84%) were in patients who had a positive blood ADV Polymerase chain reaction (PCR) alone or in combination with positive ADV PCR/ Direct Immunofluorescence Assay (DFA) at another site. Respiratory symptoms with or without pneumonia were the most common presentation (10/19, 53%). In the majority of blood positive courses (10/16, 63%), viral clearance was also accompanied by clinical response. This was not the case in four courses where patients expired despite viral clearance, including one in which death was directly attributable to adenovirus. There was reversible renal dysfunction observed during the use of CDV.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_5",
            "content": "Conclusions: CDV appeared safe and reasonably tolerated for treatment of ADV in this pediatric population and was associated with viral response and clinical improvement in the majority of patients but reversible renal dysfunction was a side effect. Further studies of the efficacy of CDV for immunocompromised children with ADV infection are warranted.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_6",
            "content": "Introduction",
            "ntype": "title",
            "meta": {
                "section": "1",
                "sec-type": "intro",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_7",
            "content": "Adenovirus (ADV) is a common cause of respiratory infection in childhood. ADV infections are usually self-limited and asymptomatic in the immunocompetent host but have been recognized as a cause of significant morbidity and mortality in immunocompromised pediatric patients such as recipients of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) <REF-1> . In these patients, ADV is an opportunistic pathogen that may lead to severe localized disease including pneumonia/pneumonitis, hepatitis, hemorrhagic cystitis or disseminated disease with multiorgan failure <REF-2> \u2013 <REF-4> . Case fatality rates in immunocompromised patients with ADV pneumonia have been reported to be as high as 60% <REF-5> . Currently, there is no FDA-labeled product available for treatment of ADV infection though several agents have been administered for this indication including ribavirin <REF-6> , <REF-7> , ganciclovir <REF-8> , vidarabine <REF-9> , <REF-10> , immune globulin <REF-11> and cidofovir <REF-12> \u2013 <REF-21> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_8",
            "content": "Cidofovir (CDV), a nucleoside and phosphonate analogue is a broad-spectrum antiviral agent that inhibits viral DNA polymerase and has broad activity in vitro against multiple viruses including all serotypes of ADV <REF-22> , <REF-23> . CDV has an FDA indication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Although this drug does not have an FDA indication for treating ADV, there is evidence of in vivo efficacy of CDV against ADV <REF-12> , <REF-14> . While CDV at a standard dose of 5mg/kg has been reported as primary therapy for treatment of ADV infection in pediatric and adult hematopoietic stem cell transplantation (HSCT) patients <REF-12> , <REF-21> , concern exists regarding potential nephrotoxicity. This associated adverse effect has limited the use of CDV for treatment of ADV infections in pediatric patients. To minimize potential toxicity of CDV, modified dosing regimens such as the use of 1 mg/kg three times weekly have been utilized <REF-14> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_9",
            "content": "Limited information regarding safety and efficacy of CDV in pediatric patients prompted us to review prior published studies in the literature and conduct a retrospective review of our inpatient use of CDV at Boston Children\u2019s Hospital (BCH).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_10",
            "content": "Methods",
            "ntype": "title",
            "meta": {
                "section": "2",
                "sec-type": "methods",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_11",
            "content": "Following Institutional Review Board (IRB) approval (IRB-P00015576), a retrospective chart review was conducted for all hospitalized patients at Boston Children\u2019s Hospital (BCH), who were prescribed CDV for adenovirus infection from January 2006 through December 2010. Depending on the clinical context, testing for adenoviruses was typically only performed in symptomatic patients, except in the case of stem cell transplant recipients who had a known history of adenovirus infection prior to transplant in which case adenovirus screening was performed routinely. The following data were collected: (1) demographic information, (2) underlying disease state, (3) type of transplant, (4) duration of cidofovir therapy, (6) serum creatinine (SCr) (baseline, peak during therapy, and level up to 2 weeks post last dose), (7) concomitant nephrotoxins prescribed (acyclovir, amikacin, cyclosporine, foscarnet, gentamicin, liposomal amphotericin B, tacrolimus, tobramycin, vancomycin, and intravenous contrast media), (8) sites of ADV detection by viral direct fluorescent antibody (DFA), nucleic acid test, and/or culture, (9) viral quantitative PCR surveillance in whole blood and other sites of infection (all specimens were tested at least weekly before, during and to two weeks post last dose of CDV to evaluate for changes in viral load with a minimum three serial values being obtained before, during and at end of therapy); (10) symptoms of infection, and clinical course including response to therapy, (11) concomitant reduction of immunosuppression and (12) mortality and cause(s) of mortality. All blood sample testing for adenovirus quantitative PCR in whole blood was performed at the Boston Children\u2019s Hospital Virology Laboratory using our laboratory developed test, using components of the Argene adenovirus kit (bioMerieux, Cambridge, MA). The Argene adenovirus kit contains primers and probes selective for a 138 base pair (bp) sequence in the Hexon gene of the adenovirus. Using a 5\u2019 nuclease assay, viral DNA is detected using the primers and fluorescent probes from the Argene kit by means of real time PCR in a Cepheid SmartCycler (Cepheid, Sunnyvale, CA). Of note, all patients who received cidofovir also received probenecid for renal protection at a standard dose of 1.25g/m 2 /dose administered 3 hours prior to and 2 hours and 8 hours after completion of each 1-hour CDV infusion. We performed a search of relevant literature up till December 2010. The literature search was conducted using PubMed, PubMed Central and Medline databases. Search terms included \u201ctreatment of adenoviral infection\u201d, \u201cpediatric\u201d, \u201cadenovirus\u201d \u201clung transplant\u201d, \u201cliver transplant\u201d, \u201cmulti-visceral transplant\u201d, \u201ckidney transplant\u201d, \u201cstem cell transplant\u201d, \u201cimmunocompromised\u201d, \u201cnephrotoxic\u201d, \u201cribavirin\u201d, \u201cganciclovir\u201d and \u201cvidarabine\u201d. As we found larger case series pertaining to use of cidofovir in stem cell transplant recipients, we excluded case reports in this population. However, given the paucity of data in solid organ transplant recipients, we included case reports.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_12",
            "content": "Definitions",
            "ntype": "title",
            "meta": {
                "section": "2.1",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_13",
            "content": "As there is no accepted definition for ADV infection or disease, we adopted definitions used in prior studies <REF-13> . Specifically, definite adenovirus disease as follows: Non-gastrointestinal locations : Symptoms and signs from the appropriate organ combined with histopathological documentation of adenovirus and/or adenovirus detection by culture, antigen test, or nucleic acid test from biopsy specimens (liver or lung), BAL fluid, or cerebrospinal fluid and without another identifiable cause; Gastrointestinal location : Symptoms together with detection of adenovirus from biopsy material by culture, antigen test, or nucleic acid test.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_14",
            "content": "Probable adenovirus disease as follows: Gastrointestinal tract : Detection of adenovirus in stool by culture, antigen test, or nucleic acid test together with symptoms; Urinary tract : Symptoms of dysuria or hematuria combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause; and Respiratory tract : Symptoms and signs of pneumonia/pneumonitis combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_15",
            "content": "Asymptomatic adenovirus infection as follows: any detection of adenovirus in an asymptomatic patient from stool, blood, urine, or upper airway specimens by viral culture, antigen tests, or PCR.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_16",
            "content": "Adenoviremia was defined as the detection of >100 copies of ADV/mL of blood (this being the lower limit of detection of the assay). Viral clearance was defined as an ADV viral load of <100 copies in blood by quantitative PCR at the end of therapy. Viral response was defined as decrease in viremia by at least one log-reduction (i.e 10-fold). Clinical resolution was defined as resolution of symptoms and/or signs of infection.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_17",
            "content": "Renal dysfunction was defined as a \u226550% increase in SCr from baseline during the course of CDV therapy. Baseline creatinine was defined as the most recent serum creatinine value prior to initiation of CDV therapy.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_18",
            "content": "Statistical analysis",
            "ntype": "title",
            "meta": {
                "section": "2.2",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_19",
            "content": "Statistical analyses employed Prism 5 for Windows Version 5.04 (GraphPad Software Inc, CA). The Mann-Whitney test was used to assess risk of renal dysfunction. Trends in adenoviremia including pre-treatment viral load, changes in viral load during therapy, and post-treatment viral load were graphed.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_20",
            "content": "Results",
            "ntype": "title",
            "meta": {
                "section": "3",
                "sec-type": "results",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_21",
            "content": "<supplementary-material xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"DS0\" xlink:href=\"https://f1000researchdata.s3.amazonaws.com/datasets/8374/e8fe44e3-75e2-4790-8421-f1b56b703133_F1000_Viremia_raw_data_LG_csv.csv\"> <label>Raw data for Figure 1</label> <caption> <p>Adenovirus blood viral load is represented in each column at each particular time in days (before or after onset of cidofovir treatment) for each patient.</p> </caption> </supplementary-material>",
            "ntype": "supplementary-material",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_22",
            "content": "<supplementary-material xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"DS1\" xlink:href=\"https://f1000researchdata.s3.amazonaws.com/datasets/8374/5d083860-06be-43fa-af52-874c2d0ef5d9_F1000_Creatinine_raw_data_csv.csv\"> <label>Raw data for Figure 2</label> <caption> <p>Nephrotoxicity - pre, peak and post serum creatinine levels in mg/dL are represented in each column for each patient.</p> </caption> </supplementary-material>",
            "ntype": "supplementary-material",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_23",
            "content": "From January 1, 2006 to December 31, 2010, a total of 16 pediatric patients received CDV for adenovirus infection at our hospital. These 16 patients received 19 courses (three patients received two separate CDV courses). The standard CDV dose of 5mg/kg weekly was used in all courses unless there was concern for renal dysfunction at the start of therapy in which case a dosing regimen of 1mg/kg three times a week was used. Patient demographics, primary diagnosis, clinical symptoms and course, and sites of adenovirus detection appear in Table 1 . Patient age ranged from 0.75\u201320 years (mean 6.5 years). Seven (44%) patients were male. Underlying primary diagnosis included 8 (50%) HSCT (1 autologous), 4 (25%) SOT, 2 (12.5%) leukemia, and 2 (6.5%) defined as other. Duration of CDV therapy ranged from 5\u201382 days (median 33.5 days).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_24",
            "content": "Table 1.",
            "ntype": "label",
            "meta": {
                "id": "T1",
                "caption": "Demographics, primary diagnosis, sites of ADV detection, clinical symptoms and course of patients included in the study. The age and gender distribution, primary diagnosis, sites of adenovirus detection, symptoms and clinical course of the patients included in the study are shown.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_25",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T1\" position=\"anchor\"> <caption> <title>Demographics, primary diagnosis, sites of ADV detection, clinical symptoms and course of patients included in the study.</title> <p>The age and gender distribution, primary diagnosis, sites of adenovirus detection, symptoms and clinical course of the patients included in the study are shown.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"center\">Pt #</th> <th align=\"left\">Age <break/>(yrs)</th> <th align=\"left\">Gender</th> <th align=\"center\">Diagnosis</th> <th align=\"center\">Site(s) of ADV <break/>detection</th> <th align=\"center\">Clinical symptoms</th> </tr> </thead> <tbody> <tr> <td align=\"center\" valign=\"top\">1a</td> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">AML - Mismatched UD Cord SCT</td> <td align=\"center\" valign=\"top\">Sp, S, R</td> <td align=\"center\" valign=\"top\">Pneumonia</td> </tr> <tr> <td align=\"center\" valign=\"top\">1b</td> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">AML - Mismatched UD Cord SCT</td> <td align=\"center\" valign=\"top\">Sp</td> <td align=\"center\" valign=\"top\">Fever and Respiratory symptoms</td> </tr> <tr> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">Severe Idiosyncratic Immunodeficiency <break/>- MRD SCT</td> <td align=\"center\" valign=\"top\">B, S</td> <td align=\"center\" valign=\"top\">Prolonged fever</td> </tr> <tr> <td align=\"center\" valign=\"top\">3</td> <td align=\"center\" valign=\"top\">3</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">AML - Chemotherapy</td> <td align=\"center\" valign=\"top\">B, S, U</td> <td align=\"center\" valign=\"top\">Pneumonia</td> </tr> <tr> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Neuroblastoma - Autologous SCT</td> <td align=\"center\" valign=\"top\">B, S, PF</td> <td align=\"center\" valign=\"top\">Prolonged fever, pericardial effusion</td> </tr> <tr> <td align=\"center\" valign=\"top\">5</td> <td align=\"center\" valign=\"top\">19</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Cystic Fibrosis - Lung Transplant</td> <td align=\"center\" valign=\"top\">B, BAL</td> <td align=\"center\" valign=\"top\">Asymptomatic</td> </tr> <tr> <td align=\"center\" valign=\"top\">*6</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Familial HLH - MUD SCT</td> <td align=\"center\" valign=\"top\">B, Sp</td> <td align=\"center\" valign=\"top\">Pneumonia, sepsis. Other <break/>co-infections including Enterococcus <break/>bacteremia, EBV viremia</td> </tr> <tr> <td align=\"center\" valign=\"top\">*7</td> <td align=\"center\" valign=\"top\">0.83</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">Persistent pulmonary hypertension, <break/>cardiomyopathy</td> <td align=\"center\" valign=\"top\">B</td> <td align=\"center\" valign=\"top\">Fever, sepsis, pneumonia. Other <break/>co-infections including <break/>stenotrophomonas bacteremia</td> </tr> <tr> <td align=\"center\" valign=\"top\">8a</td> <td align=\"center\" valign=\"top\">20</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">ALL - MRD SCT and MUD SCT</td> <td align=\"center\" valign=\"top\">BAL, B, U</td> <td align=\"center\" valign=\"top\">Pneumonia</td> </tr> <tr> <td align=\"center\" valign=\"top\">8b</td> <td align=\"center\" valign=\"top\">20</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">ALL - MRD SCT and MUD SCT</td> <td align=\"center\" valign=\"top\">S</td> <td align=\"center\" valign=\"top\">Asymptomatic</td> </tr> <tr> <td align=\"center\" valign=\"top\">9</td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Congenital Nephrotic Syndrome &amp; <break/>Hepatoblastoma - Combined Liver &amp; <break/>Kidney Transplant</td> <td align=\"center\" valign=\"top\">B,Sp</td> <td align=\"center\" valign=\"top\">Respiratory symptoms</td> </tr> <tr> <td align=\"center\" valign=\"top\">*10</td> <td align=\"center\" valign=\"top\">0.75</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">HLH - SCT</td> <td align=\"center\" valign=\"top\">S, B, U</td> <td align=\"center\" valign=\"top\">Fever, sepsis, diarrhea</td> </tr> <tr> <td align=\"center\" valign=\"top\">*11</td> <td align=\"center\" valign=\"top\">5</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">CID and Lymphoproliferative Disorder <break/>- Mismatched UD Cord SCT</td> <td align=\"center\" valign=\"top\">B</td> <td align=\"center\" valign=\"top\">Fever, respiratory symptoms, diarrhea, <break/>hemorrhagic cystitis</td> </tr> <tr> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Congenital Cardiac Defect - Heart <break/>Transplant</td> <td align=\"center\" valign=\"top\">B</td> <td align=\"center\" valign=\"top\">Fever, sepsis</td> </tr> <tr> <td align=\"center\" valign=\"top\">13</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">ALL - Chemotherapy</td> <td align=\"center\" valign=\"top\">B, S</td> <td align=\"center\" valign=\"top\">Fever, respiratory symptoms</td> </tr> <tr> <td align=\"center\" valign=\"top\">14</td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">F</td> <td align=\"center\" valign=\"top\">Cerebral Palsy</td> <td align=\"center\" valign=\"top\">B</td> <td align=\"center\" valign=\"top\">Pneumonia</td> </tr> <tr> <td align=\"center\" valign=\"top\">15a</td> <td align=\"center\" valign=\"top\">1.8</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">Hepatoblastoma - Multivisceral <break/>Transplant</td> <td align=\"center\" valign=\"top\">B, S</td> <td align=\"center\" valign=\"top\">Increased stoma output, rejection, <break/>biopsy proven ADV In stoma mucosa</td> </tr> <tr> <td align=\"center\" valign=\"top\">15b</td> <td align=\"center\" valign=\"top\">1.8</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">Hepatoblastoma - Multiviseral Transplant</td> <td align=\"center\" valign=\"top\">B, S</td> <td align=\"center\" valign=\"top\">Increased stoma output</td> </tr> <tr> <td align=\"center\" valign=\"top\">*16</td> <td align=\"center\" valign=\"top\">17</td> <td align=\"center\" valign=\"top\">M</td> <td align=\"center\" valign=\"top\">AML - MUD SCT</td> <td align=\"center\" valign=\"top\">B, U</td> <td align=\"center\" valign=\"top\">Hemorrhagic cystitis. Other <break/>co-infections including BK viruria and <break/>EBV viremia</td> </tr> </tbody> </table> <table-wrap-foot> <fn> <p>ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CID, congenital immunodeficiency; CML, chronic myelogenous leukemia; HLH, hemophagocytic lymphohistiocytosis; MRD, matched related donor; MUD, matched unrelated donor; Pt #, patient number; SCID, severe combined immunodeficiency disorder; SCT, stem cell transplant; UD, unrelated donor; Yrs, years; Site of adenovirus detection: S, stool, Sp, sputum, B, blood, BAL, bronchoalveolar lavage, R, respiratory DFA, CSF, cerebrospinal fluid, U, Urine, PF, Pericardial Fluid; *indicates patient expired</p> </fn> </table-wrap-foot> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T1",
                "caption": "Demographics, primary diagnosis, sites of ADV detection, clinical symptoms and course of patients included in the study. The age and gender distribution, primary diagnosis, sites of adenovirus detection, symptoms and clinical course of the patients included in the study are shown.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_26",
            "content": "Of the 19 courses prescribed ( Table 1 ), two courses were prescribed in a patient with definite adenovirus disease of the gastrointestinal tract, 15 courses were prescribed in patients with probable disease and two courses were prescribed in patients with asymptomatic infection. Sixteen courses (84%) were in patients who had a positive blood ADV PCR either in whole blood only or in combination with positive ADV PCR of sputum, stool, urine, broncho-alveolar lavage (BAL) fluid, pericardial fluid or positive sputum adenoviral DFA sample. Respiratory symptoms were the most common presentation (10 courses, 53%) of which six courses were prescribed for patients with respiratory symptoms and radiological evidence of pneumonia. Two courses were prescribed in patients who presented with prolonged fevers; four courses were prescribed in patients who had worsening diarrhea and colitis, two of which were biopsy proven adenovirus infection; four courses were prescribed in patients with viral sepsis with or without pneumonia; and two courses were administered in patients with severe hemorrhagic cystitis. One course was prescribed in a patient with asymptomatic respiratory tract infection and one course was prescribed in another patient with asymptomatic gastrointestinal infection.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_27",
            "content": "We further examined the 16 blood-positive courses to assess trends in ADV viral load pre-, during and post- CDV therapy ( Figure 1 ). A quantitative reduction in viral load was seen in 15 blood positive courses (94%) with viral clearance achieved in 14 (88%). Of note, all solid organ transplant recipients treated with CDV also had concomitant decrease in their immunosuppression. A single patient (Patient 6) did not demonstrate viral response to therapy and expired. The majority of adenovirus blood-positive CDV courses (10/16, 63%) were associated with clinical improvement with viral clearance; however this was not the case in four courses. Patients 7, 10, 11 and 16 expired despite demonstrating viral clearance. Patients 6, 7 and 16 had multiple other co-infections. Patients 11 and 16 developed severe hemorrhagic cystitis. Patient 11 experienced significant complications of hemorrhagic cystitis including urinary tract obstruction, renal failure and bladder perforation. Patient 16 also had concomitant BK Polyoma virus detected in the urine.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_28",
            "content": "Figure 1.",
            "ntype": "label",
            "meta": {
                "id": "f1",
                "caption": "Kinetics of Adenovirus blood viral load under cidofovir treatment. Viral loads of 16 patients with quantitative blood adenovirus PCR treated with cidofovir, are shown. Day of therapy \u22640 denotes pre-treatment viral loads. Up to two post-treatment values are shown where available and informative. Each patient\u2019s individual treatment duration is shown in the legend. + denotes patient expired.",
                "uri": "https://f1000researchdata.s3.amazonaws.com/manuscripts/11225/6f76d3c5-0171-4662-92c5-6eab18dc7369_figure1.gif",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_29",
            "content": "<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" fig-type=\"figure\" id=\"f1\" position=\"float\"> <caption> <title>Kinetics of Adenovirus blood viral load under cidofovir treatment.</title> <p>Viral loads of 16 patients with quantitative blood adenovirus PCR treated with cidofovir, are shown. Day of therapy &#8804;0 denotes pre-treatment viral loads. Up to two post-treatment values are shown where available and informative. Each patient&#8217;s individual treatment duration is shown in the legend. + denotes patient expired.</p> </caption> <graphic xlink:href=\"https://f1000researchdata.s3.amazonaws.com/manuscripts/11225/6f76d3c5-0171-4662-92c5-6eab18dc7369_figure1.gif\"/> </fig>",
            "ntype": "fig",
            "meta": {
                "id": "f1",
                "caption": "Kinetics of Adenovirus blood viral load under cidofovir treatment. Viral loads of 16 patients with quantitative blood adenovirus PCR treated with cidofovir, are shown. Day of therapy \u22640 denotes pre-treatment viral loads. Up to two post-treatment values are shown where available and informative. Each patient\u2019s individual treatment duration is shown in the legend. + denotes patient expired.",
                "uri": "https://f1000researchdata.s3.amazonaws.com/manuscripts/11225/6f76d3c5-0171-4662-92c5-6eab18dc7369_figure1.gif",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_30",
            "content": "Each patient\u2019s medication profile was assessed to determine the number of additional nephrotoxic agents concomitantly prescribed during CDV therapy (from Day 1 to 7 days post last CDV dose) ( Table 2 ).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_31",
            "content": "Table 2.",
            "ntype": "label",
            "meta": {
                "id": "T2",
                "caption": "Additional nephrotoxic agents prescribed and changes in serum creatinine during cidofovir therapy. Absolute values for serum creatinine in mg/dL for each patient are represented pre-treatment, during treatment (peak serum creatinine), and post-treatment. Additional nephrotoxic agents that each patient received are also represented.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_32",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T2\" position=\"anchor\"> <caption> <title>Additional nephrotoxic agents prescribed and changes in serum creatinine during cidofovir therapy.</title> <p>Absolute values for serum creatinine in mg/dL for each patient are represented pre-treatment, during treatment (peak serum creatinine), and post-treatment. Additional nephrotoxic agents that each patient received are also represented.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"center\" valign=\"top\">Pt #</th> <th align=\"left\" valign=\"top\">Pre-treatment <break/> Serum Cr</th> <th align=\"left\" valign=\"top\">Peak Serum <break/> Cr</th> <th align=\"center\" valign=\"top\">Post-treatment <break/> Serum Cr</th> <th align=\"center\" valign=\"top\">Additional nephrotoxic agents</th> </tr> </thead> <tbody> <tr> <td align=\"center\" valign=\"top\">1a</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">1.2</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"top\">ambisome, cyclosporine, gentamicin</td> </tr> <tr> <td align=\"center\" valign=\"top\">1b</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"bottom\">1</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"top\">cyclosporine</td> </tr> <tr> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"bottom\">0.5</td> <td align=\"center\" valign=\"top\">cyclosporine, ganciclovir, pentamidine</td> </tr> <tr> <td align=\"center\" valign=\"top\">3</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"top\">vancomycin, ambisome, gentamicin</td> </tr> <tr> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"top\">acyclovir</td> </tr> <tr> <td align=\"center\" valign=\"top\">5</td> <td align=\"center\" valign=\"bottom\">0.4</td> <td align=\"center\" valign=\"bottom\">0.7</td> <td align=\"center\" valign=\"bottom\">0.5</td> <td align=\"center\" valign=\"top\">tacrolimus</td> </tr> <tr> <td align=\"center\" valign=\"top\">6</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.4</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"top\">ambisome, ganciclovir, pentamidine, tacrolimus, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">7</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.5</td> <td align=\"center\" valign=\"bottom\">0.7</td> <td align=\"center\" valign=\"top\">gentamicin,</td> </tr> <tr> <td align=\"center\" valign=\"top\">8a</td> <td align=\"center\" valign=\"bottom\">1</td> <td align=\"center\" valign=\"bottom\">1.7</td> <td align=\"center\" valign=\"bottom\">0.4</td> <td align=\"center\" valign=\"top\">ambisome, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">8b</td> <td align=\"center\" valign=\"bottom\">0.4</td> <td align=\"center\" valign=\"bottom\">2.6</td> <td align=\"center\" valign=\"bottom\">1.3</td> <td align=\"center\" valign=\"top\">ganciclovir, tacrolimus, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">9</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">2.7</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"top\">chemotherapy, immunosuppression</td> </tr> <tr> <td align=\"center\" valign=\"top\">10</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"top\">acyclovir, ambisome, cyclosporine, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">11</td> <td align=\"center\" valign=\"bottom\">0.4</td> <td align=\"center\" valign=\"bottom\">1.6</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"top\">gentamicin, acyclovir, ambisome, cyclosporine, foscarnet, <break/> ganciclovir</td> </tr> <tr> <td align=\"center\" valign=\"top\">12</td> <td align=\"center\" valign=\"bottom\">0.5</td> <td align=\"center\" valign=\"bottom\">1.6</td> <td align=\"center\" valign=\"bottom\">0.6</td> <td align=\"center\" valign=\"top\">gentamicin, ganciclovir, tacrolimus</td> </tr> <tr> <td align=\"center\" valign=\"top\">13</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"top\">ambisome,foscarnet,ganciclovir</td> </tr> <tr> <td align=\"center\" valign=\"top\">14</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"top\">vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">15a</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"top\">tacrolimus, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">15b</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">0.2</td> <td align=\"center\" valign=\"top\">tacrolimus, vancomycin</td> </tr> <tr> <td align=\"center\" valign=\"top\">16</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"bottom\">0.5</td> <td align=\"center\" valign=\"bottom\">0.3</td> <td align=\"center\" valign=\"top\">cyclosporine, gentamicin, vancomycin, contrast</td> </tr> </tbody> </table> <table-wrap-foot> <fn> <p>Pt #, patient number; Cr, creatinine; all creatinine values are in mg/dL.</p> </fn> </table-wrap-foot> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T2",
                "caption": "Additional nephrotoxic agents prescribed and changes in serum creatinine during cidofovir therapy. Absolute values for serum creatinine in mg/dL for each patient are represented pre-treatment, during treatment (peak serum creatinine), and post-treatment. Additional nephrotoxic agents that each patient received are also represented.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_33",
            "content": "Administration of CDV was significantly associated with occurrence of renal dysfunction when comparing the peak Cr measured during CDV therapy to the baseline serum Cr (p=0.0016). Eleven courses (58%) were associated with development of renal dysfunction. Cr increased by a mean of ~50% from baseline during CDV therapy.. Of the courses with elevation in serum creatinine, 64% demonstrated return to pre-treatment creatinine levels following cessation of CDV therapy.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_34",
            "content": "Discussion",
            "ntype": "title",
            "meta": {
                "section": "4",
                "sec-type": "discussion",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_35",
            "content": "In this retrospective review of patients treated with CDV for adenovirus infection at our hospital during a 5-year period, we assessed the safety and potential efficacy of the medication in pediatric patients. Our review yielded a case series of 16 patients. While the number of patients is modest, this series adds to the existing literature describing the use of CDV in pediatric recipients of HSCT, SOT and chemotherapy for oncologic diagnoses ( Table 3 ).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_36",
            "content": "Table 3.",
            "ntype": "label",
            "meta": {
                "id": "T3",
                "caption": "Summary of studies describing use of cidofovir in pediatric HSCT and SOT recipients. Published studies in the literature describing use of cidofovir in pediatric HSCT and SOT recipients are summarized. Toxicities, and clinical outcomes reported in each study are highlighted.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_37",
            "content": "<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"T3\" position=\"anchor\"> <caption> <title>Summary of studies describing use of cidofovir in pediatric HSCT and SOT recipients.</title> <p>Published studies in the literature describing use of cidofovir in pediatric HSCT and SOT recipients are summarized. Toxicities, and clinical outcomes reported in each study are highlighted.</p> </caption> <table content-type=\"article-table\" frame=\"hsides\"> <thead> <tr> <th align=\"center\" valign=\"top\">Study</th> <th align=\"center\" valign=\"top\"># Patients <break/>(N)</th> <th align=\"center\" valign=\"top\">Clinical Setting</th> <th align=\"center\" valign=\"top\">Median <break/>Age</th> <th align=\"left\" valign=\"top\">Cidofovir dosage</th> <th align=\"left\" valign=\"top\">Duration <break/>of <break/>cidofovir <break/>use</th> <th align=\"left\" valign=\"top\">Potential <break/>Toxicity</th> <th align=\"left\" valign=\"top\">Outcome</th> </tr> </thead> <tbody> <tr> <td align=\"center\" valign=\"top\">Hoffman <sup> <xref ref-type=\"bibr\" rid=\"ref-14\">14</xref> </sup> </td> <td align=\"center\" valign=\"top\">8</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">7 yrs</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose <break/>three times weekly <break/>x 9 doses or until <break/>clearance</td> <td align=\"left\" valign=\"top\">3 weeks-8 <break/>months</td> <td align=\"left\" valign=\"top\">Well tolerated; <break/>no toxicity <break/>reported</td> <td align=\"left\" valign=\"top\">100% viral <break/>suppression <break/>3 recurrences <break/>4 expired (2 <break/>ADV-related)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Muller <sup> <xref ref-type=\"bibr\" rid=\"ref-12\">12</xref> </sup> </td> <td align=\"center\" valign=\"top\">10</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">Not <break/>reported</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose <break/>weekly up to 6 <break/>weeks, then every <break/>other week for 3 <break/>more doses</td> <td align=\"left\" valign=\"top\">3 weeks-6 <break/>months</td> <td align=\"left\" valign=\"top\">30% <break/>nephrotoxicity <break/>(50% increase <break/>Cr)</td> <td align=\"left\" valign=\"top\">9 virologic <break/>clearance <break/>5 recurrences <break/>1 expired <break/>(interstitial <break/>pneumonitis)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Anderson <sup> <xref ref-type=\"bibr\" rid=\"ref-19\">19</xref> </sup> </td> <td align=\"center\" valign=\"top\">7</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">1.5 yrs</td> <td align=\"left\" valign=\"top\">Preemptive <break/>therapy: 1 mg/kg/ <break/>dose three times <break/>weekly x 3 weeks</td> <td align=\"left\" valign=\"top\">3 weeks</td> <td align=\"left\" valign=\"top\">Well tolerated <break/>without <break/>significant <break/>toxicity reported</td> <td align=\"left\" valign=\"top\">No patient <break/>developed ADV <break/>viremia <break/>2 expired (non- <break/>ADV related)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Bhadri <sup> <xref ref-type=\"bibr\" rid=\"ref-15\">15</xref> </sup> </td> <td align=\"center\" valign=\"top\">23</td> <td align=\"center\" valign=\"top\">87% HSCT <break/>13% oncologic <break/>receiving <break/>chemotherapy</td> <td align=\"center\" valign=\"top\">5.7 yrs</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose <break/>weekly, 3 mg/kg/ <break/>dose weekly or 1 <break/>mg/kg/dose three <break/>times weekly</td> <td align=\"left\" valign=\"top\">Median <break/>6 weeks <break/>(1&#8211;26 <break/>weeks)</td> <td align=\"left\" valign=\"top\">9% Grade 1 <break/>nephrotoxicity <break/>defined by <break/>increase of <break/>creatinine up to <break/>1.5 times upper <break/>limit of normal </td> <td align=\"left\" valign=\"top\">85% of 20 <break/>evaluable <break/>patients <break/>considered <break/>successful <break/>by Ljungman criteria <sup> <xref ref-type=\"bibr\" rid=\"ref-13\">13</xref> </sup> <break/>17 expired</td> </tr> <tr> <td align=\"center\" valign=\"top\">Yusuf <sup> <xref ref-type=\"bibr\" rid=\"ref-17\">17</xref> </sup> </td> <td align=\"center\" valign=\"top\">57</td> <td align=\"center\" valign=\"top\">90% HSCT <break/>10% oncologic <break/>receiving <break/>chemotherapy</td> <td align=\"center\" valign=\"top\">8 yrs</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose <break/>weekly x2 weeks, <break/>then every other <break/>week until 3 <break/>negative ADV <break/>samples</td> <td align=\"left\" valign=\"top\">Median <break/>60 days <break/>(1 week-9 <break/>months) </td> <td align=\"left\" valign=\"top\">No toxicity <break/>reported</td> <td align=\"left\" valign=\"top\">98% successful <break/>viral clearance <break/>14% recurrence <break/>29 expired (1 <break/>ADV-related <break/>death)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Legrand <sup> <xref ref-type=\"bibr\" rid=\"ref-18\">18</xref> </sup> </td> <td align=\"center\" valign=\"top\">7</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">6.4 yrs</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose <break/>weekly x3 wks <break/>then every other <break/>wk or 10 days</td> <td align=\"left\" valign=\"top\">25&#8211;330 <break/>days</td> <td align=\"left\" valign=\"top\">43% <break/>nephrotoxicity</td> <td align=\"left\" valign=\"top\">71% deemed <break/>recovered <break/>2 expired (1 <break/>ADV related <break/>death)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Sivaprakasam <sup> <xref ref-type=\"bibr\" rid=\"ref-26\">26</xref> </sup> </td> <td align=\"center\" valign=\"top\">8</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">11 yrs</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose <break/>3 times weekly <break/>(4 patients also <break/>received IV <break/>ribavirin <break/>5 mg/kg 3 times <break/>daily)</td> <td align=\"left\" valign=\"top\">Not <break/>reported</td> <td align=\"left\" valign=\"top\">2 cases marrow <break/>failure, 1 case <break/>nephropathy</td> <td align=\"left\" valign=\"top\">3 expired <break/>(attributed <break/>to ADV and <break/>GVHD)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Williams <sup> <xref ref-type=\"bibr\" rid=\"ref-27\">27</xref> </sup> </td> <td align=\"center\" valign=\"top\">9</td> <td align=\"center\" valign=\"top\">HSCT</td> <td align=\"center\" valign=\"top\">3 yrs</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose <break/>once weekly <break/>until 3 weeks of <break/>negative results or <break/>pt no longer high <break/>risk; if underlying <break/>renal dysfunction <break/>1 mg/kg/dose 3 <break/>times weekly</td> <td align=\"left\" valign=\"top\">Median <break/>8 doses <break/>(3&#8211;32 <break/>doses)</td> <td align=\"left\" valign=\"top\">22% renal <break/>failure <break/>(compared to <break/>80% untreated <break/>comparator <break/>group)</td> <td align=\"left\" valign=\"top\">89% ADV <break/>clearance <break/>3 expired (1 <break/>ADV related)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Engelmann <sup> <xref ref-type=\"bibr\" rid=\"ref-16\">16</xref> </sup> </td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">Liver transplant</td> <td align=\"center\" valign=\"top\">7 months</td> <td align=\"left\" valign=\"top\">6 mg/kg/dose x1 <break/>with 1 repeat dose <break/>6 days later</td> <td align=\"left\" valign=\"top\">2 weeks</td> <td align=\"left\" valign=\"top\">No toxicity <break/>reported</td> <td align=\"left\" valign=\"top\">Liver rejection; <break/>reported to <break/>have slow <break/>recovery</td> </tr> <tr> <td align=\"center\" valign=\"top\">Wallot <sup> <xref ref-type=\"bibr\" rid=\"ref-20\">20</xref> </sup> </td> <td align=\"center\" valign=\"top\">2</td> <td align=\"center\" valign=\"top\">Liver transplant</td> <td align=\"center\" valign=\"top\">8 months and <break/>14 months</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose <break/>three times weekly </td> <td align=\"left\" valign=\"top\">5&#8211;8 weeks</td> <td align=\"left\" valign=\"top\">1 moderate <break/>neutropenia, 1 <break/>transient rise in <break/>creatinine</td> <td align=\"left\" valign=\"top\">Blood PCR ADV <break/>clearance in <break/>both patients <break/>No deaths</td> </tr> <tr> <td align=\"center\" valign=\"top\">Carter <sup> <xref ref-type=\"bibr\" rid=\"ref-24\">24</xref> </sup> </td> <td align=\"center\" valign=\"top\">1</td> <td align=\"center\" valign=\"top\">Liver transplant</td> <td align=\"center\" valign=\"top\">7 months</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose <break/>three times weekly </td> <td align=\"left\" valign=\"top\">7 weeks</td> <td align=\"left\" valign=\"top\">Transient <break/>acidosis and <break/>proteinuria </td> <td align=\"left\" valign=\"top\">ADV viral <break/>culture and <break/>blood PCR <break/>became <break/>negative</td> </tr> <tr> <td align=\"center\" valign=\"top\">Doan <sup> <xref ref-type=\"bibr\" rid=\"ref-25\">25</xref> </sup> </td> <td align=\"center\" valign=\"top\">4</td> <td align=\"center\" valign=\"top\">Lung transplant</td> <td align=\"center\" valign=\"top\">&lt;3 yrs</td> <td align=\"left\" valign=\"top\">1 mg/kg/dose <break/>every other day to <break/>three times weekly <break/>plus IVIG <break/>(1 pt increased <break/>dose to 2 mg/kg/ <break/>dose; <break/>1 pt increased <break/>frequency to <break/>daily therapy x 2 <break/>weeks)</td> <td align=\"left\" valign=\"top\">4 weeks</td> <td align=\"left\" valign=\"top\">No toxicity <break/>reported</td> <td align=\"left\" valign=\"top\">75% negative <break/>blood ADV PCR <break/>1 death</td> </tr> <tr> <td align=\"center\" valign=\"top\">Siedemann <sup> <xref ref-type=\"bibr\" rid=\"ref-29\">29</xref> </sup> </td> <td align=\"center\" valign=\"top\">6</td> <td align=\"center\" valign=\"top\">70% Liver <break/>transplant <break/>15% HSCT <break/>15% combined <break/>liver and HSCT</td> <td align=\"center\" valign=\"top\">2 yrs</td> <td align=\"left\" valign=\"top\">5 mg/kg/dose <break/>once weekly</td> <td align=\"left\" valign=\"top\">Not <break/>reported</td> <td align=\"left\" valign=\"top\">Not reported</td> <td align=\"left\" valign=\"top\">3 expired (all <break/>ADV related)</td> </tr> <tr> <td align=\"center\" valign=\"top\">Leurez-Ville <sup> <xref ref-type=\"bibr\" rid=\"ref-30\">30</xref> </sup> </td> <td align=\"center\" valign=\"top\">37 <break/>(8 patients <break/>with <break/>disseminated <break/>infection)</td> <td align=\"center\" valign=\"top\">60% HSCT <break/>20% solid organ <break/>transplant (1 liver, <break/>2 small bowel, 5 <break/>combined liver <break/>and small bowel) <break/>20% congenital <break/>immunodeficiency</td> <td align=\"center\" valign=\"top\">2.2 yrs (only <break/>cases of <break/>disseminated <break/>infection <break/>reported)</td> <td align=\"left\" valign=\"top\">5mg/kg/dose <break/>once weekly <break/>for two weeks <break/>followed by <break/>5mg/kg every 2 <break/>weeks or 10 days; <break/>only patients with <break/>disseminated <break/>infection received <break/>cidofovir)</td> <td align=\"left\" valign=\"top\">Not <break/>reported</td> <td align=\"left\" valign=\"top\">1 patient with <break/>persistent <break/>nephroxicity <break/>requiring dose <break/>adjustment of <break/>cidofovir</td> <td align=\"left\" valign=\"top\">60% with <break/>disseminated <break/>infection <break/>recovered <break/>3 patients with <break/>disseminated <break/>infection <break/>expired</td> </tr> </tbody> </table> </table-wrap>",
            "ntype": "table-wrap",
            "meta": {
                "id": "T3",
                "caption": "Summary of studies describing use of cidofovir in pediatric HSCT and SOT recipients. Published studies in the literature describing use of cidofovir in pediatric HSCT and SOT recipients are summarized. Toxicities, and clinical outcomes reported in each study are highlighted.",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_38",
            "content": "Similar to other studies the majority of our patients had received a HSCT or had an oncologic diagnosis and received chemotherapy. We identified eight publications describing the use of CDV for adenovirus infection in the setting of HSCT or oncologic diagnoses treated with chemotherapy ( Table 3 ). Three of these studies <REF-14> , <REF-17> , <REF-27> reported viral clearance in 89\u2013100% of their patients. We observed similar rates of viral clearance (88%) but this was not consistently associated with clinical improvement.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_39",
            "content": "There are very few reports on the use of CDV for adenovirus infection in pediatric SOT recipients, which have largely been restricted to reports of children receiving liver or lung transplants <REF-16> , <REF-20> , <REF-24> , <REF-25> , <REF-29> , <REF-30> . We identified six publications reporting the use of CDV for adenovirus infection in pediatric SOT recipients limited to one to four per report with the majority of these children having received liver or lung transplants <REF-16> , <REF-20> , <REF-24> , <REF-25> , <REF-29> , <REF-30> . Doan et al. <REF-25> described children who had received lung transplants with reported viral clearance in three of their four patients. Our case series contributes patients who received several types of SOT including lung, heart, combined kidney and liver, and multi-visceral transplants. All patients with SOT in our series demonstrated viral clearance as well as resolution of symptoms, which may have reflected a combination of both the antiviral effect of CDV coupled with reduced immunosuppression. Interestingly, a prospective study performed in adult liver, kidney and heart transplant recipients noted the transient nature of adenoviremia and self limited infection in this population even in the absence of any treatment or interventions <REF-28> . However, the authors also note that the majority of patients in whom adenoviremia was detected in their study were asymptomatic or only mildly symptomatic, and thus differed from patients with severe infections who are more frequently reported in the pediatric transplant population and in lung allograft recipients. In contrast, Seidemann and colleagues <REF-29> report mortality in 2 of 5 pediatric solid organ transplant recipients despite the use of cidofovir in their case series. Similarly, Leurez-Ville et al. <REF-30> report mortality in 1 of 3 pediatric solid organ transplant recipients with disseminated adenovirus infection. The patients who expired in both these reports had severe symptoms and ultimately died of septic multiorgan failure. With the exception of a lung transplant recipient, all other solid organ transplant recipients with adenovirus infection in our study were more than mildly symptomatic. While other reports suggest the possibility of self-resolution of adenoviremia and absence of significant clinical sequelae in asymptomatic or mildly symptomatic solid organ transplant recipients, the propensity for serious infections and mortality has also been highlighted in the pediatric specific solid organ transplant literature <REF-29> , <REF-30> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_40",
            "content": "Two-thirds of our patients experienced resolution of their symptoms and had an overall favorable clinical course with recovery. However, one-third died all of whom were stem cell transplant recipients. With the exception of one patient it is unclear whether adenovirus was the direct cause of mortality in these patients. Our observations are consistent with what has been reported in the literature pertaining to outcomes in stem cell transplant recipients with adenovirus infections who have been treated with CDV <REF-9> , <REF-12> , <REF-14> , <REF-18> , <REF-23> , <REF-27> . Among SCT patients mortality remains high (10%\u201370%) even when clearance from blood is seen. It is hence difficult to conclude from these data whether or not cidofovir provided any clinical benefit. It should also be noted that two patients in our series received cidofovir despite being asymptomatic. One such patient was a lung transplant recipient in whom adenovirus was detected in both blood and BAL fluid, the other was a stem cell transplant recipient with a prior history of recurrent viremia and pneumonia. Both these patients were considered to be at high risk for complications from adenovirus infection thus leading to the decision to use cidofovir.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_41",
            "content": "In our case series, renal dysfunction was common during CDV therapy with patients experiencing an average 50% increase of serum creatinine from their baseline. However, renal dysfunction was transient in the majority of patients with serum creatinine returning to baseline after cessation of CDV therapy. While some studies have reported no toxicities related to the use of CDV <REF-14> , <REF-16> , <REF-17> , <REF-19> , <REF-25> , the transient nature of nephrotoxicity observed has been reported by other studies <REF-20> , <REF-24> . Finally, brincidofovir (CMX001), an orally administered lipid -conjugate derivative of cidofovir is currently being investigated in clinical trials and is reported to have no nephrotoxicity <REF-31> .",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_42",
            "content": "Our study has several limitations. Most notably, the small number of patients precluded evaluation of other factors that may impact infection resolution such as immunosuppressive regimens, and additional factors that may impact degree of renal dysfunction. Nevertheless, our study adds to the limited reported literature of pediatric ADV patients treated with CDV.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_43",
            "content": "Data availability",
            "ntype": "title",
            "meta": {
                "section": "5",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_44",
            "content": "The data referenced by this article are under copyright with the following copyright statement: Copyright: \u00ef\u00bf\u00bd 2016 Ganapathi L et al.",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_45",
            "content": "Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_46",
            "content": "F1000Research : Dataset 1. Raw data for Figure 1 , 10.5256/f1000research.8374.d117321 <REF-32>",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_47",
            "content": "F1000Research : Dataset 2. Raw data for Figure 2, 10.5256/f1000research.8374.d117322 <REF-33>",
            "ntype": "p",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_48",
            "content": "<REF-1> Ison MG : Adenovirus infections in transplant recipients. Clin Infect Dis. 2006 ; 43 ( 3 ): 331 \u2013 339 . 16804849 10.1086/505498",
            "ntype": "ref",
            "meta": {
                "id": "ref-1",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_49",
            "content": "<REF-2> Carrigan DR : Adenovirus infections in immunocompromised patients. Am J Med. 1997 ; 102 ( 3A ): 71 \u2013 74 . 10868146",
            "ntype": "ref",
            "meta": {
                "id": "ref-2",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_50",
            "content": "<REF-4> Hale GA Heslop HE Krance RA : Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999 ; 23 ( 3 ): 277 \u2013 282 . 10084260 10.1038/sj.bmt.1701563",
            "ntype": "ref",
            "meta": {
                "id": "ref-4",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_51",
            "content": "<REF-5> Hierholzer JC : Adenoviruses in the immunocompromised host. Clin Microbiol Rev. 1992 ; 5 ( 3 ): 262 \u2013 274 . 1323383 358244 10.1128/CMR.5.3.262",
            "ntype": "ref",
            "meta": {
                "id": "ref-5",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_52",
            "content": "<REF-6> Gavin PJ Katz BZ : Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics. 2002 ; 110 ( 1 Pt 1 ): e9 . 12093990",
            "ntype": "ref",
            "meta": {
                "id": "ref-6",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_53",
            "content": "<REF-7> McCarthy AJ Bergin M De Silva LM : Intravenous ribavirin therapy for disseminated adenovirus infection. Pediatr Infect Dis J. 1995 ; 14 ( 11 ): 1003 \u2013 1004 . 8584339 10.1097/00006454-199511000-00017",
            "ntype": "ref",
            "meta": {
                "id": "ref-7",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_54",
            "content": "<REF-8> Chen FE Liang RH Lo JY : Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant. 1997 ; 20 ( 11 ): 997 \u2013 999 . 9422482 10.1038/sj.bmt.1700997",
            "ntype": "ref",
            "meta": {
                "id": "ref-8",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_55",
            "content": "<REF-9> Kawakami M Ueda S Maeda T : Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997 ; 20 ( 6 ): 485 \u2013 490 . 9313882 10.1038/sj.bmt.1700923",
            "ntype": "ref",
            "meta": {
                "id": "ref-9",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_56",
            "content": "<REF-10> Kitabayashi A Hirokawa M Kuroki J : Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 ; 14 ( 5 ): 853 \u2013 854 . 7889020",
            "ntype": "ref",
            "meta": {
                "id": "ref-10",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_57",
            "content": "<REF-11> Saquib R Melton LB Chandrakantan A : Disseminated adenovirus infection in renal transplant recipients: the role of cidofovir and intravenous immunoglobulin. Transpl Infect Dis. 2010 ; 12 ( 1 ): 77 \u2013 83 . 19761559 10.1111/j.1399-3062.2009.00452.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-11",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_58",
            "content": "<REF-12> Muller WJ Levin MJ Shin YK : Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis. 2005 ; 41 ( 12 ): 1812 \u2013 1816 . 16288409 10.1086/498151",
            "ntype": "ref",
            "meta": {
                "id": "ref-12",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_59",
            "content": "<REF-13> Ljungman P Ribaud P Eyrich M : Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2003 ; 31 ( 6 ): 481 \u2013 486 . 12665844 10.1038/sj.bmt.1703798",
            "ntype": "ref",
            "meta": {
                "id": "ref-13",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_60",
            "content": "<REF-14> Hoffman JA Shah AJ Ross LA : Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001 ; 7 ( 7 ): 388 \u2013 394 . 11529489 10.1053/bbmt.2001.v7.pm11529489",
            "ntype": "ref",
            "meta": {
                "id": "ref-14",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_61",
            "content": "<REF-16> Engelmann G Heim A Greil J : Adenovirus infection and treatment with cidofovir in children after liver transplantation. Pediatr Transplant. 2009 ; 13 ( 4 ): 421 \u2013 428 . 18783361 10.1111/j.1399-3046.2008.01014.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-16",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_62",
            "content": "<REF-17> Yusuf U Hale GA Carr J : Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation. 2006 ; 81 ( 10 ): 1398 \u2013 1404 . 16732176 10.1097/01.tp.0000209195.95115.8e",
            "ntype": "ref",
            "meta": {
                "id": "ref-17",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_63",
            "content": "<REF-18> Legrand F Berrebi D Houhou N : Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 2001 ; 27 ( 6 ): 621 \u2013 626 . 11319592 10.1038/sj.bmt.1702820",
            "ntype": "ref",
            "meta": {
                "id": "ref-18",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_64",
            "content": "<REF-19> Anderson EJ Guzman-Cottrill JA Kletzel M : High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant. 2008 ; 12 ( 2 ): 219 \u2013 227 . 18307672 10.1111/j.1399-3046.2007.00851.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-19",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_65",
            "content": "<REF-20> Wallot MA Dohna-Schwake C Auth M : Disseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: impact of intravenous cidofovir and inhaled nitric oxide. Pediatr Transplant. 2006 ; 10 ( 1 ): 121 \u2013 127 . 16499602 10.1111/j.1399-3046.2005.00411.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-20",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_66",
            "content": "<REF-21> Ribaud P Scieux C Freymuth F : Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis. 1999 ; 28 ( 3 ): 690 \u2013 691 . 10194105 10.1086/517222",
            "ntype": "ref",
            "meta": {
                "id": "ref-21",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_67",
            "content": "<REF-22> Naesens L Lenaerts L Andrei G : Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother. 2005 ; 49 ( 3 ): 1010 \u2013 1016 . 15728896 10.1128/AAC.49.3.1010-1016.2005 549266",
            "ntype": "ref",
            "meta": {
                "id": "ref-22",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_68",
            "content": "<REF-23> Morfin F Dupuis-Girod S Mundweiler S : In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther. 2005 ; 10 ( 2 ): 225 \u2013 229 . 15865216",
            "ntype": "ref",
            "meta": {
                "id": "ref-23",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_69",
            "content": "<REF-24> Carter BA Karpen SJ Quiros-Tejeira RE : Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation. 2002 ; 74 ( 7 ): 1050 \u2013 1052 . 12394854",
            "ntype": "ref",
            "meta": {
                "id": "ref-24",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_70",
            "content": "<REF-25> Doan ML Mallory GB Kaplan SL : Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant. 2007 ; 26 ( 9 ): 883 \u2013 889 . 17845926 10.1016/j.healun.2007.06.009",
            "ntype": "ref",
            "meta": {
                "id": "ref-25",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_71",
            "content": "<REF-27> Williams KM Agwu AL Dabb AA : A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection. J Pediatr Hematol Oncol. 2009 ; 31 ( 11 ): 825 \u2013 831 . 19801951 10.1097/MPH.0b013e3181b7873e 4251427",
            "ntype": "ref",
            "meta": {
                "id": "ref-27",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_72",
            "content": "<REF-28> Humar A Kumar D Mazzulli T : A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant. 2005 ; 5 ( 10 ): 2555 \u2013 9 . 16162207 10.1111/j.1600-6143.2005.01033.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-28",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_73",
            "content": "<REF-29> Seidemann K Heim A Pfister ED : Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am J Transplant. 2004 ; 4 ( 12 ): 2102 \u2013 8 . 15575915 10.1111/j.1600-6143.2004.00631.x",
            "ntype": "ref",
            "meta": {
                "id": "ref-29",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_74",
            "content": "<REF-30> Leruez-Ville M Minard V Lacaille F : Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis. 2004 ; 38 ( 1 ): 45 \u2013 52 . 14679447 10.1086/380450",
            "ntype": "ref",
            "meta": {
                "id": "ref-30",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_75",
            "content": "<REF-31> Wold WS Toth K : New drug on the horizon for treating adenovirus. Expert Opin Pharmacother. 2015 ; 16 ( 14 ): 2095 \u2013 9 . 26330121 10.1517/14656566.2015.1083975 4866633",
            "ntype": "ref",
            "meta": {
                "id": "ref-31",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_76",
            "content": "<REF-32> Ganapathi L Arnold A Jones S : Dataset 1 in: Use of cidofovir in pediatric patients with adenovirus infection. F1000Research. 2016 . Data Source",
            "ntype": "ref",
            "meta": {
                "id": "ref-32",
                "created_by": "F1000XMLParser"
            }
        },
        {
            "ix": "5-758_v2_77",
            "content": "<REF-33> Ganapathi L Arnold A Jones S : Dataset 2 in: Use of cidofovir in pediatric patients with adenovirus infection. F1000Research. 2016 . Data Source",
            "ntype": "ref",
            "meta": {
                "id": "ref-33",
                "created_by": "F1000XMLParser"
            }
        }
    ],
    "span_nodes": [
        {
            "ix": "5-758_v2_0@0",
            "content": "Use of cidofovir in pediatric patients with adenovirus infection",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_0",
            "start": 0,
            "end": 63,
            "label": {}
        },
        {
            "ix": "5-758_v2_1@0",
            "content": "Abstract",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_1",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "5-758_v2_2@0",
            "content": "Background : Adenoviruses contribute to morbidity and mortality among immunocompromised pediatric patients including stem cell and solid organ transplant recipients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_2",
            "start": 0,
            "end": 164,
            "label": {}
        },
        {
            "ix": "5-758_v2_2@1",
            "content": "Cidofovir (CDV), an antiviral compound approved by the FDA in 1996, is used for treatment of adenoviral (ADV) infections in immunocompromised patients despite concern of potential nephrotoxicity.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_2",
            "start": 166,
            "end": 360,
            "label": {}
        },
        {
            "ix": "5-758_v2_3@0",
            "content": "Methods : We conducted a retrospective 5-year review at Boston Children\u2019s Hospital of 16 patients (mean age = 6.5 years) receiving 19 courses of CDV.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_3",
            "start": 0,
            "end": 148,
            "label": {}
        },
        {
            "ix": "5-758_v2_3@1",
            "content": "During therapy all pertinent data elements were reviewed to characterize potential response to therapy and incidence of renal dysfunction.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_3",
            "start": 150,
            "end": 287,
            "label": {}
        },
        {
            "ix": "5-758_v2_4@0",
            "content": "Results: Of the 19 CDV courses prescribed, 16 courses (84%) were in patients who had a positive blood ADV Polymerase chain reaction (PCR) alone or in combination with positive ADV PCR/ Direct Immunofluorescence Assay (DFA) at another site.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_4",
            "start": 0,
            "end": 238,
            "label": {}
        },
        {
            "ix": "5-758_v2_4@1",
            "content": "Respiratory symptoms with or without pneumonia were the most common presentation (10/19, 53%).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_4",
            "start": 240,
            "end": 333,
            "label": {}
        },
        {
            "ix": "5-758_v2_4@2",
            "content": "In the majority of blood positive courses (10/16, 63%), viral clearance was also accompanied by clinical response.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_4",
            "start": 335,
            "end": 448,
            "label": {}
        },
        {
            "ix": "5-758_v2_4@3",
            "content": "This was not the case in four courses where patients expired despite viral clearance, including one in which death was directly attributable to adenovirus.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_4",
            "start": 450,
            "end": 604,
            "label": {}
        },
        {
            "ix": "5-758_v2_4@4",
            "content": "There was reversible renal dysfunction observed during the use of CDV.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_4",
            "start": 606,
            "end": 675,
            "label": {}
        },
        {
            "ix": "5-758_v2_5@0",
            "content": "Conclusions: CDV appeared safe and reasonably tolerated for treatment of ADV in this pediatric population and was associated with viral response and clinical improvement in the majority of patients but reversible renal dysfunction was a side effect.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_5",
            "start": 0,
            "end": 248,
            "label": {}
        },
        {
            "ix": "5-758_v2_5@1",
            "content": "Further studies of the efficacy of CDV for immunocompromised children with ADV infection are warranted.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_5",
            "start": 250,
            "end": 352,
            "label": {}
        },
        {
            "ix": "5-758_v2_6@0",
            "content": "Introduction",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_6",
            "start": 0,
            "end": 11,
            "label": {}
        },
        {
            "ix": "5-758_v2_7@0",
            "content": "Adenovirus (ADV) is a common cause of respiratory infection in childhood.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_7",
            "start": 0,
            "end": 72,
            "label": {}
        },
        {
            "ix": "5-758_v2_7@1",
            "content": "ADV infections are usually self-limited and asymptomatic in the immunocompetent host but have been recognized as a cause of significant morbidity and mortality in immunocompromised pediatric patients such as recipients of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) <REF-1> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_7",
            "start": 74,
            "end": 379,
            "label": {}
        },
        {
            "ix": "5-758_v2_7@2",
            "content": "In these patients, ADV is an opportunistic pathogen that may lead to severe localized disease including pneumonia/pneumonitis, hepatitis, hemorrhagic cystitis or disseminated disease with multiorgan failure <REF-2> \u2013 <REF-4> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_7",
            "start": 381,
            "end": 606,
            "label": {}
        },
        {
            "ix": "5-758_v2_7@3",
            "content": "Case fatality rates in immunocompromised patients with ADV pneumonia have been reported to be as high as 60% <REF-5> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_7",
            "start": 608,
            "end": 725,
            "label": {}
        },
        {
            "ix": "5-758_v2_7@4",
            "content": "Currently, there is no FDA-labeled product available for treatment of ADV infection though several agents have been administered for this indication including ribavirin <REF-6> , <REF-7> , ganciclovir <REF-8> , vidarabine <REF-9> , <REF-10> , immune globulin <REF-11> and cidofovir <REF-12> \u2013 <REF-21> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_7",
            "start": 727,
            "end": 1029,
            "label": {}
        },
        {
            "ix": "5-758_v2_8@0",
            "content": "Cidofovir (CDV), a nucleoside and phosphonate analogue is a broad-spectrum antiviral agent that inhibits viral DNA polymerase and has broad activity in vitro against multiple viruses including all serotypes of ADV <REF-22> , <REF-23> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_8",
            "start": 0,
            "end": 234,
            "label": {}
        },
        {
            "ix": "5-758_v2_8@1",
            "content": "CDV has an FDA indication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_8",
            "start": 236,
            "end": 336,
            "label": {}
        },
        {
            "ix": "5-758_v2_8@2",
            "content": "Although this drug does not have an FDA indication for treating ADV, there is evidence of in vivo efficacy of CDV against ADV <REF-12> , <REF-14> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_8",
            "start": 338,
            "end": 484,
            "label": {}
        },
        {
            "ix": "5-758_v2_8@3",
            "content": "While CDV at a standard dose of 5mg/kg has been reported as primary therapy for treatment of ADV infection in pediatric and adult hematopoietic stem cell transplantation (HSCT) patients <REF-12> , <REF-21> , concern exists regarding potential nephrotoxicity.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_8",
            "start": 486,
            "end": 743,
            "label": {}
        },
        {
            "ix": "5-758_v2_8@4",
            "content": "This associated adverse effect has limited the use of CDV for treatment of ADV infections in pediatric patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_8",
            "start": 745,
            "end": 856,
            "label": {}
        },
        {
            "ix": "5-758_v2_8@5",
            "content": "To minimize potential toxicity of CDV, modified dosing regimens such as the use of 1 mg/kg three times weekly have been utilized <REF-14> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_8",
            "start": 858,
            "end": 996,
            "label": {}
        },
        {
            "ix": "5-758_v2_9@0",
            "content": "Limited information regarding safety and efficacy of CDV in pediatric patients prompted us to review prior published studies in the literature and conduct a retrospective review of our inpatient use of CDV at Boston Children\u2019s Hospital (BCH).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_9",
            "start": 0,
            "end": 241,
            "label": {}
        },
        {
            "ix": "5-758_v2_10@0",
            "content": "Methods",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_10",
            "start": 0,
            "end": 6,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@0",
            "content": "Following Institutional Review Board (IRB) approval (IRB-P00015576), a retrospective chart review was conducted for all hospitalized patients at Boston Children\u2019s Hospital (BCH), who were prescribed CDV for adenovirus infection from January 2006 through December 2010.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 0,
            "end": 267,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@1",
            "content": "Depending on the clinical context, testing for adenoviruses was typically only performed in symptomatic patients, except in the case of stem cell transplant recipients who had a known history of adenovirus infection prior to transplant in which case adenovirus screening was performed routinely.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 269,
            "end": 563,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@2",
            "content": "The following data were collected: (1) demographic information, (2) underlying disease state, (3) type of transplant, (4) duration of cidofovir therapy, (6) serum creatinine (SCr) (baseline, peak during therapy, and level up to 2 weeks post last dose), (7) concomitant nephrotoxins prescribed (acyclovir, amikacin, cyclosporine, foscarnet, gentamicin, liposomal amphotericin B, tacrolimus, tobramycin, vancomycin, and intravenous contrast media), (8) sites of ADV detection by viral direct fluorescent antibody (DFA), nucleic acid test, and/or culture, (9) viral quantitative PCR surveillance in whole blood and other sites of infection (all specimens were tested at least weekly before, during and to two weeks post last dose of CDV to evaluate for changes in viral load with a minimum three serial values being obtained before, during and at end of therapy); (10) symptoms of infection, and clinical course including response to therapy, (11) concomitant reduction of immunosuppression and (12) mortality and cause(s) of mortality.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 565,
            "end": 1597,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@3",
            "content": "All blood sample testing for adenovirus quantitative PCR in whole blood was performed at the Boston Children\u2019s Hospital Virology Laboratory using our laboratory developed test, using components of the Argene adenovirus kit (bioMerieux, Cambridge, MA).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 1599,
            "end": 1849,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@4",
            "content": "The Argene adenovirus kit contains primers and probes selective for a 138 base pair (bp) sequence in the Hexon gene of the adenovirus.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 1851,
            "end": 1984,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@5",
            "content": "Using a 5\u2019 nuclease assay, viral DNA is detected using the primers and fluorescent probes from the Argene kit by means of real time PCR in a Cepheid SmartCycler (Cepheid, Sunnyvale, CA).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 1986,
            "end": 2171,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@6",
            "content": "Of note, all patients who received cidofovir also received probenecid for renal protection at a standard dose of 1.25g/m 2 /dose administered 3 hours prior to and 2 hours and 8 hours after completion of each 1-hour CDV infusion.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 2173,
            "end": 2400,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@7",
            "content": "We performed a search of relevant literature up till December 2010.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 2402,
            "end": 2468,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@8",
            "content": "The literature search was conducted using PubMed, PubMed Central and Medline databases.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 2470,
            "end": 2556,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@9",
            "content": "Search terms included \u201ctreatment of adenoviral infection\u201d, \u201cpediatric\u201d, \u201cadenovirus\u201d \u201clung transplant\u201d, \u201cliver transplant\u201d, \u201cmulti-visceral transplant\u201d, \u201ckidney transplant\u201d, \u201cstem cell transplant\u201d, \u201cimmunocompromised\u201d, \u201cnephrotoxic\u201d, \u201cribavirin\u201d, \u201cganciclovir\u201d and \u201cvidarabine\u201d.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 2558,
            "end": 2835,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@10",
            "content": "As we found larger case series pertaining to use of cidofovir in stem cell transplant recipients, we excluded case reports in this population.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 2837,
            "end": 2978,
            "label": {}
        },
        {
            "ix": "5-758_v2_11@11",
            "content": "However, given the paucity of data in solid organ transplant recipients, we included case reports.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_11",
            "start": 2980,
            "end": 3077,
            "label": {}
        },
        {
            "ix": "5-758_v2_12@0",
            "content": "Definitions",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_12",
            "start": 0,
            "end": 10,
            "label": {}
        },
        {
            "ix": "5-758_v2_13@0",
            "content": "As there is no accepted definition for ADV infection or disease, we adopted definitions used in prior studies <REF-13> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_13",
            "start": 0,
            "end": 119,
            "label": {}
        },
        {
            "ix": "5-758_v2_13@1",
            "content": "Specifically, definite adenovirus disease as follows: Non-gastrointestinal locations : Symptoms and signs from the appropriate organ combined with histopathological documentation of adenovirus and/or adenovirus detection by culture, antigen test, or nucleic acid test from biopsy specimens (liver or lung), BAL fluid, or cerebrospinal fluid and without another identifiable cause; Gastrointestinal location : Symptoms together with detection of adenovirus from biopsy material by culture, antigen test, or nucleic acid test.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_13",
            "start": 121,
            "end": 644,
            "label": {}
        },
        {
            "ix": "5-758_v2_14@0",
            "content": "Probable adenovirus disease as follows: Gastrointestinal tract : Detection of adenovirus in stool by culture, antigen test, or nucleic acid test together with symptoms; Urinary tract : Symptoms of dysuria or hematuria combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause; and Respiratory tract : Symptoms and signs of pneumonia/pneumonitis combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_14",
            "start": 0,
            "end": 526,
            "label": {}
        },
        {
            "ix": "5-758_v2_15@0",
            "content": "Asymptomatic adenovirus infection as follows: any detection of adenovirus in an asymptomatic patient from stool, blood, urine, or upper airway specimens by viral culture, antigen tests, or PCR.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_15",
            "start": 0,
            "end": 192,
            "label": {}
        },
        {
            "ix": "5-758_v2_16@0",
            "content": "Adenoviremia was defined as the detection of >100 copies of ADV/mL of blood (this being the lower limit of detection of the assay).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_16",
            "start": 0,
            "end": 130,
            "label": {}
        },
        {
            "ix": "5-758_v2_16@1",
            "content": "Viral clearance was defined as an ADV viral load of <100 copies in blood by quantitative PCR at the end of therapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_16",
            "start": 132,
            "end": 246,
            "label": {}
        },
        {
            "ix": "5-758_v2_16@2",
            "content": "Viral response was defined as decrease in viremia by at least one log-reduction (i.e 10-fold).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_16",
            "start": 248,
            "end": 341,
            "label": {}
        },
        {
            "ix": "5-758_v2_16@3",
            "content": "Clinical resolution was defined as resolution of symptoms and/or signs of infection.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_16",
            "start": 343,
            "end": 426,
            "label": {}
        },
        {
            "ix": "5-758_v2_17@0",
            "content": "Renal dysfunction was defined as a \u226550% increase in SCr from baseline during the course of CDV therapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_17",
            "start": 0,
            "end": 102,
            "label": {}
        },
        {
            "ix": "5-758_v2_17@1",
            "content": "Baseline creatinine was defined as the most recent serum creatinine value prior to initiation of CDV therapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_17",
            "start": 104,
            "end": 212,
            "label": {}
        },
        {
            "ix": "5-758_v2_18@0",
            "content": "Statistical analysis",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_18",
            "start": 0,
            "end": 19,
            "label": {}
        },
        {
            "ix": "5-758_v2_19@0",
            "content": "Statistical analyses employed Prism 5 for Windows Version 5.04 (GraphPad Software Inc, CA).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_19",
            "start": 0,
            "end": 90,
            "label": {}
        },
        {
            "ix": "5-758_v2_19@1",
            "content": "The Mann-Whitney test was used to assess risk of renal dysfunction.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_19",
            "start": 92,
            "end": 158,
            "label": {}
        },
        {
            "ix": "5-758_v2_19@2",
            "content": "Trends in adenoviremia including pre-treatment viral load, changes in viral load during therapy, and post-treatment viral load were graphed.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_19",
            "start": 160,
            "end": 299,
            "label": {}
        },
        {
            "ix": "5-758_v2_20@0",
            "content": "Results",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_20",
            "start": 0,
            "end": 6,
            "label": {}
        },
        {
            "ix": "5-758_v2_23@0",
            "content": "From January 1, 2006 to December 31, 2010, a total of 16 pediatric patients received CDV for adenovirus infection at our hospital.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_23",
            "start": 0,
            "end": 129,
            "label": {}
        },
        {
            "ix": "5-758_v2_23@1",
            "content": "These 16 patients received 19 courses (three patients received two separate CDV courses).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_23",
            "start": 131,
            "end": 219,
            "label": {}
        },
        {
            "ix": "5-758_v2_23@2",
            "content": "The standard CDV dose of 5mg/kg weekly was used in all courses unless there was concern for renal dysfunction at the start of therapy in which case a dosing regimen of 1mg/kg three times a week was used.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_23",
            "start": 221,
            "end": 423,
            "label": {}
        },
        {
            "ix": "5-758_v2_23@3",
            "content": "Patient demographics, primary diagnosis, clinical symptoms and course, and sites of adenovirus detection appear in Table 1 .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_23",
            "start": 425,
            "end": 548,
            "label": {}
        },
        {
            "ix": "5-758_v2_23@4",
            "content": "Patient age ranged from 0.75\u201320 years (mean 6.5 years).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_23",
            "start": 550,
            "end": 604,
            "label": {}
        },
        {
            "ix": "5-758_v2_23@5",
            "content": "Seven (44%) patients were male.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_23",
            "start": 606,
            "end": 636,
            "label": {}
        },
        {
            "ix": "5-758_v2_23@6",
            "content": "Underlying primary diagnosis included 8 (50%) HSCT (1 autologous), 4 (25%) SOT, 2 (12.5%) leukemia, and 2 (6.5%) defined as other.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_23",
            "start": 638,
            "end": 767,
            "label": {}
        },
        {
            "ix": "5-758_v2_23@7",
            "content": "Duration of CDV therapy ranged from 5\u201382 days (median 33.5 days).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_23",
            "start": 769,
            "end": 833,
            "label": {}
        },
        {
            "ix": "5-758_v2_24@0",
            "content": "Table 1.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_24",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "5-758_v2_26@0",
            "content": "Of the 19 courses prescribed ( Table 1 ), two courses were prescribed in a patient with definite adenovirus disease of the gastrointestinal tract, 15 courses were prescribed in patients with probable disease and two courses were prescribed in patients with asymptomatic infection.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_26",
            "start": 0,
            "end": 279,
            "label": {}
        },
        {
            "ix": "5-758_v2_26@1",
            "content": "Sixteen courses (84%) were in patients who had a positive blood ADV PCR either in whole blood only or in combination with positive ADV PCR of sputum, stool, urine, broncho-alveolar lavage (BAL) fluid, pericardial fluid or positive sputum adenoviral DFA sample.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_26",
            "start": 281,
            "end": 540,
            "label": {}
        },
        {
            "ix": "5-758_v2_26@2",
            "content": "Respiratory symptoms were the most common presentation (10 courses, 53%) of which six courses were prescribed for patients with respiratory symptoms and radiological evidence of pneumonia.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_26",
            "start": 542,
            "end": 729,
            "label": {}
        },
        {
            "ix": "5-758_v2_26@3",
            "content": "Two courses were prescribed in patients who presented with prolonged fevers; four courses were prescribed in patients who had worsening diarrhea and colitis, two of which were biopsy proven adenovirus infection; four courses were prescribed in patients with viral sepsis with or without pneumonia; and two courses were administered in patients with severe hemorrhagic cystitis.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_26",
            "start": 731,
            "end": 1107,
            "label": {}
        },
        {
            "ix": "5-758_v2_26@4",
            "content": "One course was prescribed in a patient with asymptomatic respiratory tract infection and one course was prescribed in another patient with asymptomatic gastrointestinal infection.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_26",
            "start": 1109,
            "end": 1287,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@0",
            "content": "We further examined the 16 blood-positive courses to assess trends in ADV viral load pre-, during and post- CDV therapy ( Figure 1 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 0,
            "end": 132,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@1",
            "content": "A quantitative reduction in viral load was seen in 15 blood positive courses (94%) with viral clearance achieved in 14 (88%).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 134,
            "end": 258,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@2",
            "content": "Of note, all solid organ transplant recipients treated with CDV also had concomitant decrease in their immunosuppression.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 260,
            "end": 380,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@3",
            "content": "A single patient (Patient 6) did not demonstrate viral response to therapy and expired.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 382,
            "end": 468,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@4",
            "content": "The majority of adenovirus blood-positive CDV courses (10/16, 63%) were associated with clinical improvement with viral clearance; however this was not the case in four courses.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 470,
            "end": 646,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@5",
            "content": "Patients 7, 10, 11 and 16 expired despite demonstrating viral clearance.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 648,
            "end": 719,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@6",
            "content": "Patients 6, 7 and 16 had multiple other co-infections.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 721,
            "end": 774,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@7",
            "content": "Patients 11 and 16 developed severe hemorrhagic cystitis.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 776,
            "end": 832,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@8",
            "content": "Patient 11 experienced significant complications of hemorrhagic cystitis including urinary tract obstruction, renal failure and bladder perforation.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 834,
            "end": 981,
            "label": {}
        },
        {
            "ix": "5-758_v2_27@9",
            "content": "Patient 16 also had concomitant BK Polyoma virus detected in the urine.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_27",
            "start": 983,
            "end": 1053,
            "label": {}
        },
        {
            "ix": "5-758_v2_28@0",
            "content": "Figure 1.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_28",
            "start": 0,
            "end": 8,
            "label": {}
        },
        {
            "ix": "5-758_v2_30@0",
            "content": "Each patient\u2019s medication profile was assessed to determine the number of additional nephrotoxic agents concomitantly prescribed during CDV therapy (from Day 1 to 7 days post last CDV dose) ( Table 2 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_30",
            "start": 0,
            "end": 201,
            "label": {}
        },
        {
            "ix": "5-758_v2_31@0",
            "content": "Table 2.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_31",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "5-758_v2_33@0",
            "content": "Administration of CDV was significantly associated with occurrence of renal dysfunction when comparing the peak Cr measured during CDV therapy to the baseline serum Cr (p=0.0016).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_33",
            "start": 0,
            "end": 178,
            "label": {}
        },
        {
            "ix": "5-758_v2_33@1",
            "content": "Eleven courses (58%) were associated with development of renal dysfunction. Cr increased by a mean of ~50% from baseline during CDV therapy..",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_33",
            "start": 180,
            "end": 320,
            "label": {}
        },
        {
            "ix": "5-758_v2_33@2",
            "content": "Of the courses with elevation in serum creatinine, 64% demonstrated return to pre-treatment creatinine levels following cessation of CDV therapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_33",
            "start": 322,
            "end": 466,
            "label": {}
        },
        {
            "ix": "5-758_v2_34@0",
            "content": "Discussion",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_34",
            "start": 0,
            "end": 9,
            "label": {}
        },
        {
            "ix": "5-758_v2_35@0",
            "content": "In this retrospective review of patients treated with CDV for adenovirus infection at our hospital during a 5-year period, we assessed the safety and potential efficacy of the medication in pediatric patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_35",
            "start": 0,
            "end": 208,
            "label": {}
        },
        {
            "ix": "5-758_v2_35@1",
            "content": "Our review yielded a case series of 16 patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_35",
            "start": 210,
            "end": 257,
            "label": {}
        },
        {
            "ix": "5-758_v2_35@2",
            "content": "While the number of patients is modest, this series adds to the existing literature describing the use of CDV in pediatric recipients of HSCT, SOT and chemotherapy for oncologic diagnoses ( Table 3 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_35",
            "start": 259,
            "end": 458,
            "label": {}
        },
        {
            "ix": "5-758_v2_36@0",
            "content": "Table 3.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_36",
            "start": 0,
            "end": 7,
            "label": {}
        },
        {
            "ix": "5-758_v2_38@0",
            "content": "Similar to other studies the majority of our patients had received a HSCT or had an oncologic diagnosis and received chemotherapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_38",
            "start": 0,
            "end": 129,
            "label": {}
        },
        {
            "ix": "5-758_v2_38@1",
            "content": "We identified eight publications describing the use of CDV for adenovirus infection in the setting of HSCT or oncologic diagnoses treated with chemotherapy ( Table 3 ).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_38",
            "start": 131,
            "end": 298,
            "label": {}
        },
        {
            "ix": "5-758_v2_38@2",
            "content": "Three of these studies <REF-14> , <REF-17> , <REF-27> reported viral clearance in 89\u2013100% of their patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_38",
            "start": 300,
            "end": 407,
            "label": {}
        },
        {
            "ix": "5-758_v2_38@3",
            "content": "We observed similar rates of viral clearance (88%) but this was not consistently associated with clinical improvement.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_38",
            "start": 409,
            "end": 526,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@0",
            "content": "There are very few reports on the use of CDV for adenovirus infection in pediatric SOT recipients, which have largely been restricted to reports of children receiving liver or lung transplants <REF-16> , <REF-20> , <REF-24> , <REF-25> , <REF-29> , <REF-30> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 0,
            "end": 257,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@1",
            "content": "We identified six publications reporting the use of CDV for adenovirus infection in pediatric SOT recipients limited to one to four per report with the majority of these children having received liver or lung transplants <REF-16> , <REF-20> , <REF-24> , <REF-25> , <REF-29> , <REF-30> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 259,
            "end": 544,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@2",
            "content": "Doan et al. <REF-25> described children who had received lung transplants with reported viral clearance in three of their four patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 546,
            "end": 681,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@3",
            "content": "Our case series contributes patients who received several types of SOT including lung, heart, combined kidney and liver, and multi-visceral transplants.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 683,
            "end": 834,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@4",
            "content": "All patients with SOT in our series demonstrated viral clearance as well as resolution of symptoms, which may have reflected a combination of both the antiviral effect of CDV coupled with reduced immunosuppression.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 836,
            "end": 1049,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@5",
            "content": "Interestingly, a prospective study performed in adult liver, kidney and heart transplant recipients noted the transient nature of adenoviremia and self limited infection in this population even in the absence of any treatment or interventions <REF-28> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 1051,
            "end": 1303,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@6",
            "content": "However, the authors also note that the majority of patients in whom adenoviremia was detected in their study were asymptomatic or only mildly symptomatic, and thus differed from patients with severe infections who are more frequently reported in the pediatric transplant population and in lung allograft recipients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 1305,
            "end": 1620,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@7",
            "content": "In contrast, Seidemann and colleagues <REF-29> report mortality in 2 of 5 pediatric solid organ transplant recipients despite the use of cidofovir in their case series.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 1622,
            "end": 1789,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@8",
            "content": "Similarly, Leurez-Ville et al. <REF-30> report mortality in 1 of 3 pediatric solid organ transplant recipients with disseminated adenovirus infection.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 1791,
            "end": 1940,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@9",
            "content": "The patients who expired in both these reports had severe symptoms and ultimately died of septic multiorgan failure.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 1942,
            "end": 2057,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@10",
            "content": "With the exception of a lung transplant recipient, all other solid organ transplant recipients with adenovirus infection in our study were more than mildly symptomatic.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 2059,
            "end": 2226,
            "label": {}
        },
        {
            "ix": "5-758_v2_39@11",
            "content": "While other reports suggest the possibility of self-resolution of adenoviremia and absence of significant clinical sequelae in asymptomatic or mildly symptomatic solid organ transplant recipients, the propensity for serious infections and mortality has also been highlighted in the pediatric specific solid organ transplant literature <REF-29> , <REF-30> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_39",
            "start": 2228,
            "end": 2583,
            "label": {}
        },
        {
            "ix": "5-758_v2_40@0",
            "content": "Two-thirds of our patients experienced resolution of their symptoms and had an overall favorable clinical course with recovery.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_40",
            "start": 0,
            "end": 126,
            "label": {}
        },
        {
            "ix": "5-758_v2_40@1",
            "content": "However, one-third died all of whom were stem cell transplant recipients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_40",
            "start": 128,
            "end": 200,
            "label": {}
        },
        {
            "ix": "5-758_v2_40@2",
            "content": "With the exception of one patient it is unclear whether adenovirus was the direct cause of mortality in these patients.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_40",
            "start": 202,
            "end": 320,
            "label": {}
        },
        {
            "ix": "5-758_v2_40@3",
            "content": "Our observations are consistent with what has been reported in the literature pertaining to outcomes in stem cell transplant recipients with adenovirus infections who have been treated with CDV <REF-9> , <REF-12> , <REF-14> , <REF-18> , <REF-23> , <REF-27> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_40",
            "start": 322,
            "end": 579,
            "label": {}
        },
        {
            "ix": "5-758_v2_40@4",
            "content": "Among SCT patients mortality remains high (10%\u201370%) even when clearance from blood is seen.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_40",
            "start": 581,
            "end": 671,
            "label": {}
        },
        {
            "ix": "5-758_v2_40@5",
            "content": "It is hence difficult to conclude from these data whether or not cidofovir provided any clinical benefit.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_40",
            "start": 673,
            "end": 777,
            "label": {}
        },
        {
            "ix": "5-758_v2_40@6",
            "content": "It should also be noted that two patients in our series received cidofovir despite being asymptomatic.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_40",
            "start": 779,
            "end": 880,
            "label": {}
        },
        {
            "ix": "5-758_v2_40@7",
            "content": "One such patient was a lung transplant recipient in whom adenovirus was detected in both blood and BAL fluid, the other was a stem cell transplant recipient with a prior history of recurrent viremia and pneumonia.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_40",
            "start": 882,
            "end": 1094,
            "label": {}
        },
        {
            "ix": "5-758_v2_40@8",
            "content": "Both these patients were considered to be at high risk for complications from adenovirus infection thus leading to the decision to use cidofovir.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_40",
            "start": 1096,
            "end": 1240,
            "label": {}
        },
        {
            "ix": "5-758_v2_41@0",
            "content": "In our case series, renal dysfunction was common during CDV therapy with patients experiencing an average 50% increase of serum creatinine from their baseline.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_41",
            "start": 0,
            "end": 158,
            "label": {}
        },
        {
            "ix": "5-758_v2_41@1",
            "content": "However, renal dysfunction was transient in the majority of patients with serum creatinine returning to baseline after cessation of CDV therapy.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_41",
            "start": 160,
            "end": 303,
            "label": {}
        },
        {
            "ix": "5-758_v2_41@2",
            "content": "While some studies have reported no toxicities related to the use of CDV <REF-14> , <REF-16> , <REF-17> , <REF-19> , <REF-25> , the transient nature of nephrotoxicity observed has been reported by other studies <REF-20> , <REF-24> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_41",
            "start": 305,
            "end": 536,
            "label": {}
        },
        {
            "ix": "5-758_v2_41@3",
            "content": "Finally, brincidofovir (CMX001), an orally administered lipid -conjugate derivative of cidofovir is currently being investigated in clinical trials and is reported to have no nephrotoxicity <REF-31> .",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_41",
            "start": 538,
            "end": 737,
            "label": {}
        },
        {
            "ix": "5-758_v2_42@0",
            "content": "Our study has several limitations.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_42",
            "start": 0,
            "end": 33,
            "label": {}
        },
        {
            "ix": "5-758_v2_42@1",
            "content": "Most notably, the small number of patients precluded evaluation of other factors that may impact infection resolution such as immunosuppressive regimens, and additional factors that may impact degree of renal dysfunction.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_42",
            "start": 35,
            "end": 255,
            "label": {}
        },
        {
            "ix": "5-758_v2_42@2",
            "content": "Nevertheless, our study adds to the limited reported literature of pediatric ADV patients treated with CDV.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_42",
            "start": 257,
            "end": 363,
            "label": {}
        },
        {
            "ix": "5-758_v2_43@0",
            "content": "Data availability",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_43",
            "start": 0,
            "end": 16,
            "label": {}
        },
        {
            "ix": "5-758_v2_44@0",
            "content": "The data referenced by this article are under copyright with the following copyright statement: Copyright: \u00ef\u00bf\u00bd 2016 Ganapathi L et al.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_44",
            "start": 0,
            "end": 133,
            "label": {}
        },
        {
            "ix": "5-758_v2_45@0",
            "content": "Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_45",
            "start": 0,
            "end": 159,
            "label": {}
        },
        {
            "ix": "5-758_v2_46@0",
            "content": "F1000Research : Dataset 1.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_46",
            "start": 0,
            "end": 25,
            "label": {}
        },
        {
            "ix": "5-758_v2_46@1",
            "content": "Raw data for Figure 1 , 10.5256/f1000research.8374.d117321 <REF-32>",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_46",
            "start": 27,
            "end": 93,
            "label": {}
        },
        {
            "ix": "5-758_v2_47@0",
            "content": "F1000Research : Dataset 2.",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_47",
            "start": 0,
            "end": 25,
            "label": {}
        },
        {
            "ix": "5-758_v2_47@1",
            "content": "Raw data for Figure 2, 10.5256/f1000research.8374.d117322 <REF-33>",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_47",
            "start": 27,
            "end": 92,
            "label": {}
        },
        {
            "ix": "5-758_v2_48@0",
            "content": "<REF-1> Ison MG : Adenovirus infections in transplant recipients. Clin Infect Dis. 2006 ; 43 ( 3 ): 331 \u2013 339 . 16804849 10.1086/505498",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_48",
            "start": 0,
            "end": 134,
            "label": {}
        },
        {
            "ix": "5-758_v2_49@0",
            "content": "<REF-2> Carrigan DR : Adenovirus infections in immunocompromised patients. Am J Med. 1997 ; 102 ( 3A ): 71 \u2013 74 . 10868146",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_49",
            "start": 0,
            "end": 121,
            "label": {}
        },
        {
            "ix": "5-758_v2_50@0",
            "content": "<REF-4> Hale GA Heslop HE Krance RA : Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999 ; 23 ( 3 ): 277 \u2013 282 . 10084260 10.1038/sj.bmt.1701563",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_50",
            "start": 0,
            "end": 187,
            "label": {}
        },
        {
            "ix": "5-758_v2_51@0",
            "content": "<REF-5> Hierholzer JC : Adenoviruses in the immunocompromised host. Clin Microbiol Rev. 1992 ; 5 ( 3 ): 262 \u2013 274 . 1323383 358244 10.1128/CMR.5.3.262",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_51",
            "start": 0,
            "end": 149,
            "label": {}
        },
        {
            "ix": "5-758_v2_52@0",
            "content": "<REF-6> Gavin PJ Katz BZ : Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics. 2002 ; 110 ( 1 Pt 1 ): e9 . 12093990",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_52",
            "start": 0,
            "end": 167,
            "label": {}
        },
        {
            "ix": "5-758_v2_53@0",
            "content": "<REF-7> McCarthy AJ Bergin M De Silva LM : Intravenous ribavirin therapy for disseminated adenovirus infection. Pediatr Infect Dis J. 1995 ; 14 ( 11 ): 1003 \u2013 1004 . 8584339 10.1097/00006454-199511000-00017",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_53",
            "start": 0,
            "end": 205,
            "label": {}
        },
        {
            "ix": "5-758_v2_54@0",
            "content": "<REF-8> Chen FE Liang RH Lo JY : Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant. 1997 ; 20 ( 11 ): 997 \u2013 999 . 9422482 10.1038/sj.bmt.1700997",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_54",
            "start": 0,
            "end": 191,
            "label": {}
        },
        {
            "ix": "5-758_v2_55@0",
            "content": "<REF-9> Kawakami M Ueda S Maeda T : Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997 ; 20 ( 6 ): 485 \u2013 490 . 9313882 10.1038/sj.bmt.1700923",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_55",
            "start": 0,
            "end": 213,
            "label": {}
        },
        {
            "ix": "5-758_v2_56@0",
            "content": "<REF-10> Kitabayashi A Hirokawa M Kuroki J : Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 ; 14 ( 5 ): 853 \u2013 854 . 7889020",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_56",
            "start": 0,
            "end": 241,
            "label": {}
        },
        {
            "ix": "5-758_v2_57@0",
            "content": "<REF-11> Saquib R Melton LB Chandrakantan A : Disseminated adenovirus infection in renal transplant recipients: the role of cidofovir and intravenous immunoglobulin. Transpl Infect Dis. 2010 ; 12 ( 1 ): 77 \u2013 83 . 19761559 10.1111/j.1399-3062.2009.00452.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_57",
            "start": 0,
            "end": 253,
            "label": {}
        },
        {
            "ix": "5-758_v2_58@0",
            "content": "<REF-12> Muller WJ Levin MJ Shin YK : Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis. 2005 ; 41 ( 12 ): 1812 \u2013 1816 . 16288409 10.1086/498151",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_58",
            "start": 0,
            "end": 253,
            "label": {}
        },
        {
            "ix": "5-758_v2_59@0",
            "content": "<REF-13> Ljungman P Ribaud P Eyrich M : Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2003 ; 31 ( 6 ): 481 \u2013 486 . 12665844 10.1038/sj.bmt.1703798",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_59",
            "start": 0,
            "end": 327,
            "label": {}
        },
        {
            "ix": "5-758_v2_60@0",
            "content": "<REF-14> Hoffman JA Shah AJ Ross LA : Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001 ; 7 ( 7 ): 388 \u2013 394 . 11529489 10.1053/bbmt.2001.v7.pm11529489",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_60",
            "start": 0,
            "end": 248,
            "label": {}
        },
        {
            "ix": "5-758_v2_61@0",
            "content": "<REF-16> Engelmann G Heim A Greil J : Adenovirus infection and treatment with cidofovir in children after liver transplantation. Pediatr Transplant. 2009 ; 13 ( 4 ): 421 \u2013 428 . 18783361 10.1111/j.1399-3046.2008.01014.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_61",
            "start": 0,
            "end": 218,
            "label": {}
        },
        {
            "ix": "5-758_v2_62@0",
            "content": "<REF-17> Yusuf U Hale GA Carr J : Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation. 2006 ; 81 ( 10 ): 1398 \u2013 1404 . 16732176 10.1097/01.tp.0000209195.95115.8e",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_62",
            "start": 0,
            "end": 234,
            "label": {}
        },
        {
            "ix": "5-758_v2_63@0",
            "content": "<REF-18> Legrand F Berrebi D Houhou N : Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 2001 ; 27 ( 6 ): 621 \u2013 626 . 11319592 10.1038/sj.bmt.1702820",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_63",
            "start": 0,
            "end": 239,
            "label": {}
        },
        {
            "ix": "5-758_v2_64@0",
            "content": "<REF-19> Anderson EJ Guzman-Cottrill JA Kletzel M : High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant. 2008 ; 12 ( 2 ): 219 \u2013 227 . 18307672 10.1111/j.1399-3046.2007.00851.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_64",
            "start": 0,
            "end": 278,
            "label": {}
        },
        {
            "ix": "5-758_v2_65@0",
            "content": "<REF-20> Wallot MA Dohna-Schwake C Auth M : Disseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: impact of intravenous cidofovir and inhaled nitric oxide. Pediatr Transplant. 2006 ; 10 ( 1 ): 121 \u2013 127 . 16499602 10.1111/j.1399-3046.2005.00411.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_65",
            "start": 0,
            "end": 292,
            "label": {}
        },
        {
            "ix": "5-758_v2_66@0",
            "content": "<REF-21> Ribaud P Scieux C Freymuth F : Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis. 1999 ; 28 ( 3 ): 690 \u2013 691 . 10194105 10.1086/517222",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_66",
            "start": 0,
            "end": 226,
            "label": {}
        },
        {
            "ix": "5-758_v2_67@0",
            "content": "<REF-22> Naesens L Lenaerts L Andrei G : Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother. 2005 ; 49 ( 3 ): 1010 \u2013 1016 . 15728896 10.1128/AAC.49.3.1010-1016.2005 549266",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_67",
            "start": 0,
            "end": 232,
            "label": {}
        },
        {
            "ix": "5-758_v2_68@0",
            "content": "<REF-23> Morfin F Dupuis-Girod S Mundweiler S : In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther. 2005 ; 10 ( 2 ): 225 \u2013 229 . 15865216",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_68",
            "start": 0,
            "end": 177,
            "label": {}
        },
        {
            "ix": "5-758_v2_69@0",
            "content": "<REF-24> Carter BA Karpen SJ Quiros-Tejeira RE : Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation. 2002 ; 74 ( 7 ): 1050 \u2013 1052 . 12394854",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_69",
            "start": 0,
            "end": 205,
            "label": {}
        },
        {
            "ix": "5-758_v2_70@0",
            "content": "<REF-25> Doan ML Mallory GB Kaplan SL : Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant. 2007 ; 26 ( 9 ): 883 \u2013 889 . 17845926 10.1016/j.healun.2007.06.009",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_70",
            "start": 0,
            "end": 220,
            "label": {}
        },
        {
            "ix": "5-758_v2_71@0",
            "content": "<REF-27> Williams KM Agwu AL Dabb AA : A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection. J Pediatr Hematol Oncol. 2009 ; 31 ( 11 ): 825 \u2013 831 . 19801951 10.1097/MPH.0b013e3181b7873e 4251427",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_71",
            "start": 0,
            "end": 293,
            "label": {}
        },
        {
            "ix": "5-758_v2_72@0",
            "content": "<REF-28> Humar A Kumar D Mazzulli T : A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant. 2005 ; 5 ( 10 ): 2555 \u2013 9 . 16162207 10.1111/j.1600-6143.2005.01033.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_72",
            "start": 0,
            "end": 212,
            "label": {}
        },
        {
            "ix": "5-758_v2_73@0",
            "content": "<REF-29> Seidemann K Heim A Pfister ED : Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am J Transplant. 2004 ; 4 ( 12 ): 2102 \u2013 8 . 15575915 10.1111/j.1600-6143.2004.00631.x",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_73",
            "start": 0,
            "end": 267,
            "label": {}
        },
        {
            "ix": "5-758_v2_74@0",
            "content": "<REF-30> Leruez-Ville M Minard V Lacaille F : Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis. 2004 ; 38 ( 1 ): 45 \u2013 52 . 14679447 10.1086/380450",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_74",
            "start": 0,
            "end": 214,
            "label": {}
        },
        {
            "ix": "5-758_v2_75@0",
            "content": "<REF-31> Wold WS Toth K : New drug on the horizon for treating adenovirus. Expert Opin Pharmacother. 2015 ; 16 ( 14 ): 2095 \u2013 9 . 26330121 10.1517/14656566.2015.1083975 4866633",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_75",
            "start": 0,
            "end": 175,
            "label": {}
        },
        {
            "ix": "5-758_v2_76@0",
            "content": "<REF-32> Ganapathi L Arnold A Jones S : Dataset 1 in: Use of cidofovir in pediatric patients with adenovirus infection. F1000Research. 2016 . Data Source",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_76",
            "start": 0,
            "end": 152,
            "label": {}
        },
        {
            "ix": "5-758_v2_77@0",
            "content": "<REF-33> Ganapathi L Arnold A Jones S : Dataset 2 in: Use of cidofovir in pediatric patients with adenovirus infection. F1000Research. 2016 . Data Source",
            "ntype": "s",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            },
            "src_ix": "5-758_v2_77",
            "start": 0,
            "end": 152,
            "label": {}
        }
    ],
    "edges": [
        {
            "src_ix": "5-758_v2_0",
            "tgt_ix": "5-758_v2_1",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_1",
            "tgt_ix": "5-758_v2_2",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_1",
            "tgt_ix": "5-758_v2_3",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_1",
            "tgt_ix": "5-758_v2_4",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_1",
            "tgt_ix": "5-758_v2_5",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_0",
            "tgt_ix": "5-758_v2_6",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_6",
            "tgt_ix": "5-758_v2_7",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_6",
            "tgt_ix": "5-758_v2_8",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_6",
            "tgt_ix": "5-758_v2_9",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_0",
            "tgt_ix": "5-758_v2_10",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_10",
            "tgt_ix": "5-758_v2_11",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_10",
            "tgt_ix": "5-758_v2_12",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_12",
            "tgt_ix": "5-758_v2_13",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_12",
            "tgt_ix": "5-758_v2_14",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_12",
            "tgt_ix": "5-758_v2_15",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_12",
            "tgt_ix": "5-758_v2_16",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_12",
            "tgt_ix": "5-758_v2_17",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_10",
            "tgt_ix": "5-758_v2_18",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_18",
            "tgt_ix": "5-758_v2_19",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_0",
            "tgt_ix": "5-758_v2_20",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_21",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_22",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_23",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_24",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_24",
            "tgt_ix": "5-758_v2_25",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_26",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_27",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_28",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_28",
            "tgt_ix": "5-758_v2_29",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_30",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_31",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_31",
            "tgt_ix": "5-758_v2_32",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_33",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_0",
            "tgt_ix": "5-758_v2_34",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_34",
            "tgt_ix": "5-758_v2_35",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_34",
            "tgt_ix": "5-758_v2_36",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_36",
            "tgt_ix": "5-758_v2_37",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_34",
            "tgt_ix": "5-758_v2_38",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_34",
            "tgt_ix": "5-758_v2_39",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_34",
            "tgt_ix": "5-758_v2_40",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_34",
            "tgt_ix": "5-758_v2_41",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_34",
            "tgt_ix": "5-758_v2_42",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_0",
            "tgt_ix": "5-758_v2_43",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_43",
            "tgt_ix": "5-758_v2_44",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_43",
            "tgt_ix": "5-758_v2_45",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_43",
            "tgt_ix": "5-758_v2_46",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_43",
            "tgt_ix": "5-758_v2_47",
            "etype": "parent",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_0",
            "tgt_ix": "5-758_v2_1",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_1",
            "tgt_ix": "5-758_v2_2",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_2",
            "tgt_ix": "5-758_v2_3",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_3",
            "tgt_ix": "5-758_v2_4",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_4",
            "tgt_ix": "5-758_v2_5",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_5",
            "tgt_ix": "5-758_v2_6",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_6",
            "tgt_ix": "5-758_v2_7",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_8",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_9",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_9",
            "tgt_ix": "5-758_v2_10",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_10",
            "tgt_ix": "5-758_v2_11",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_12",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_12",
            "tgt_ix": "5-758_v2_13",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_13",
            "tgt_ix": "5-758_v2_14",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_14",
            "tgt_ix": "5-758_v2_15",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_15",
            "tgt_ix": "5-758_v2_16",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_16",
            "tgt_ix": "5-758_v2_17",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_17",
            "tgt_ix": "5-758_v2_18",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_18",
            "tgt_ix": "5-758_v2_19",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_19",
            "tgt_ix": "5-758_v2_20",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_21",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_21",
            "tgt_ix": "5-758_v2_22",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_22",
            "tgt_ix": "5-758_v2_23",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_24",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_24",
            "tgt_ix": "5-758_v2_25",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_25",
            "tgt_ix": "5-758_v2_26",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_26",
            "tgt_ix": "5-758_v2_27",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_28",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_28",
            "tgt_ix": "5-758_v2_29",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_29",
            "tgt_ix": "5-758_v2_30",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_30",
            "tgt_ix": "5-758_v2_31",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_31",
            "tgt_ix": "5-758_v2_32",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_32",
            "tgt_ix": "5-758_v2_33",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_33",
            "tgt_ix": "5-758_v2_34",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_34",
            "tgt_ix": "5-758_v2_35",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_35",
            "tgt_ix": "5-758_v2_36",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_36",
            "tgt_ix": "5-758_v2_37",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_37",
            "tgt_ix": "5-758_v2_38",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_38",
            "tgt_ix": "5-758_v2_39",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_40",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_41",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_41",
            "tgt_ix": "5-758_v2_42",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_42",
            "tgt_ix": "5-758_v2_43",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_43",
            "tgt_ix": "5-758_v2_44",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_44",
            "tgt_ix": "5-758_v2_45",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_45",
            "tgt_ix": "5-758_v2_46",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_46",
            "tgt_ix": "5-758_v2_47",
            "etype": "next",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_48",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_49",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_50",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_51",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_52",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_53",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_54",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_55",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_56",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_57",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_58",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_13",
            "tgt_ix": "5-758_v2_59",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_60",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_61",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_38",
            "tgt_ix": "5-758_v2_62",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_63",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_41",
            "tgt_ix": "5-758_v2_64",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_65",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_66",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_67",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_68",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_69",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_70",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_38",
            "tgt_ix": "5-758_v2_71",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_72",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_73",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_74",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_41",
            "tgt_ix": "5-758_v2_75",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_46",
            "tgt_ix": "5-758_v2_76",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_47",
            "tgt_ix": "5-758_v2_77",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_25",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_29",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_30",
            "tgt_ix": "5-758_v2_32",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_35",
            "tgt_ix": "5-758_v2_37",
            "etype": "link",
            "meta": {
                "created_by": "F1000XMLParser"
            }
        },
        {
            "src_ix": "5-758_v2_0",
            "tgt_ix": "5-758_v2_0@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_1",
            "tgt_ix": "5-758_v2_1@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_2",
            "tgt_ix": "5-758_v2_2@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_2",
            "tgt_ix": "5-758_v2_2@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_3",
            "tgt_ix": "5-758_v2_3@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_3",
            "tgt_ix": "5-758_v2_3@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_4",
            "tgt_ix": "5-758_v2_4@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_4",
            "tgt_ix": "5-758_v2_4@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_4",
            "tgt_ix": "5-758_v2_4@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_4",
            "tgt_ix": "5-758_v2_4@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_4",
            "tgt_ix": "5-758_v2_4@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_5",
            "tgt_ix": "5-758_v2_5@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_5",
            "tgt_ix": "5-758_v2_5@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_6",
            "tgt_ix": "5-758_v2_6@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_7@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_7@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_7@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_7@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_7",
            "tgt_ix": "5-758_v2_7@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_8@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_8@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_8@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_8@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_8@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_8",
            "tgt_ix": "5-758_v2_8@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_9",
            "tgt_ix": "5-758_v2_9@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_10",
            "tgt_ix": "5-758_v2_10@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@8",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@9",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@10",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_11",
            "tgt_ix": "5-758_v2_11@11",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_12",
            "tgt_ix": "5-758_v2_12@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_13",
            "tgt_ix": "5-758_v2_13@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_13",
            "tgt_ix": "5-758_v2_13@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_14",
            "tgt_ix": "5-758_v2_14@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_15",
            "tgt_ix": "5-758_v2_15@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_16",
            "tgt_ix": "5-758_v2_16@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_16",
            "tgt_ix": "5-758_v2_16@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_16",
            "tgt_ix": "5-758_v2_16@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_16",
            "tgt_ix": "5-758_v2_16@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_17",
            "tgt_ix": "5-758_v2_17@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_17",
            "tgt_ix": "5-758_v2_17@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_18",
            "tgt_ix": "5-758_v2_18@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_19",
            "tgt_ix": "5-758_v2_19@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_19",
            "tgt_ix": "5-758_v2_19@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_19",
            "tgt_ix": "5-758_v2_19@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_20",
            "tgt_ix": "5-758_v2_20@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_23@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_23@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_23@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_23@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_23@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_23@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_23@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_23",
            "tgt_ix": "5-758_v2_23@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_24",
            "tgt_ix": "5-758_v2_24@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_26",
            "tgt_ix": "5-758_v2_26@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_26",
            "tgt_ix": "5-758_v2_26@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_26",
            "tgt_ix": "5-758_v2_26@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_26",
            "tgt_ix": "5-758_v2_26@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_26",
            "tgt_ix": "5-758_v2_26@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@8",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_27",
            "tgt_ix": "5-758_v2_27@9",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_28",
            "tgt_ix": "5-758_v2_28@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_30",
            "tgt_ix": "5-758_v2_30@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_31",
            "tgt_ix": "5-758_v2_31@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_33",
            "tgt_ix": "5-758_v2_33@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_33",
            "tgt_ix": "5-758_v2_33@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_33",
            "tgt_ix": "5-758_v2_33@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_34",
            "tgt_ix": "5-758_v2_34@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_35",
            "tgt_ix": "5-758_v2_35@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_35",
            "tgt_ix": "5-758_v2_35@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_35",
            "tgt_ix": "5-758_v2_35@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_36",
            "tgt_ix": "5-758_v2_36@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_38",
            "tgt_ix": "5-758_v2_38@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_38",
            "tgt_ix": "5-758_v2_38@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_38",
            "tgt_ix": "5-758_v2_38@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_38",
            "tgt_ix": "5-758_v2_38@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@8",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@9",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@10",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_39",
            "tgt_ix": "5-758_v2_39@11",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_40@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_40@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_40@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_40@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_40@4",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_40@5",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_40@6",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_40@7",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_40",
            "tgt_ix": "5-758_v2_40@8",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_41",
            "tgt_ix": "5-758_v2_41@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_41",
            "tgt_ix": "5-758_v2_41@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_41",
            "tgt_ix": "5-758_v2_41@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_41",
            "tgt_ix": "5-758_v2_41@3",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_42",
            "tgt_ix": "5-758_v2_42@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_42",
            "tgt_ix": "5-758_v2_42@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_42",
            "tgt_ix": "5-758_v2_42@2",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_43",
            "tgt_ix": "5-758_v2_43@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_44",
            "tgt_ix": "5-758_v2_44@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_45",
            "tgt_ix": "5-758_v2_45@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_46",
            "tgt_ix": "5-758_v2_46@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_46",
            "tgt_ix": "5-758_v2_46@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_47",
            "tgt_ix": "5-758_v2_47@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_47",
            "tgt_ix": "5-758_v2_47@1",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_48",
            "tgt_ix": "5-758_v2_48@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_49",
            "tgt_ix": "5-758_v2_49@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_50",
            "tgt_ix": "5-758_v2_50@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_51",
            "tgt_ix": "5-758_v2_51@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_52",
            "tgt_ix": "5-758_v2_52@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_53",
            "tgt_ix": "5-758_v2_53@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_54",
            "tgt_ix": "5-758_v2_54@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_55",
            "tgt_ix": "5-758_v2_55@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_56",
            "tgt_ix": "5-758_v2_56@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_57",
            "tgt_ix": "5-758_v2_57@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_58",
            "tgt_ix": "5-758_v2_58@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_59",
            "tgt_ix": "5-758_v2_59@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_60",
            "tgt_ix": "5-758_v2_60@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_61",
            "tgt_ix": "5-758_v2_61@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_62",
            "tgt_ix": "5-758_v2_62@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_63",
            "tgt_ix": "5-758_v2_63@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_64",
            "tgt_ix": "5-758_v2_64@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_65",
            "tgt_ix": "5-758_v2_65@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_66",
            "tgt_ix": "5-758_v2_66@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_67",
            "tgt_ix": "5-758_v2_67@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_68",
            "tgt_ix": "5-758_v2_68@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_69",
            "tgt_ix": "5-758_v2_69@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_70",
            "tgt_ix": "5-758_v2_70@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_71",
            "tgt_ix": "5-758_v2_71@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_72",
            "tgt_ix": "5-758_v2_72@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_73",
            "tgt_ix": "5-758_v2_73@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_74",
            "tgt_ix": "5-758_v2_74@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_75",
            "tgt_ix": "5-758_v2_75@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_76",
            "tgt_ix": "5-758_v2_76@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        },
        {
            "src_ix": "5-758_v2_77",
            "tgt_ix": "5-758_v2_77@0",
            "etype": "link",
            "meta": {
                "created_by": "IntertextSentenceSplitter_all"
            }
        }
    ],
    "prefix": "5-758_v2",
    "meta": {
        "parser": "F1000XMLParser",
        "intertext-graph": "N/A",
        "doi": "10.12688/f1000research.8374.2",
        "atype": "research-note",
        "license": "http://creativecommons.org/licenses/by/4.0/",
        "title": "Use of cidofovir in pediatric patients with adenovirus infection",
        "abstract": "Background : Adenoviruses contribute to morbidity and mortality among immunocompromised pediatric patients including stem cell and solid organ transplant recipients. Cidofovir (CDV), an antiviral compound approved by the FDA in 1996, is used for treatment of adenoviral (ADV) infections in immunocompromised patients despite concern of potential nephrotoxicity. Methods : We conducted a retrospective 5-year review at Boston Children\u2019s Hospital of 16 patients (mean age = 6.5 years) receiving 19 courses of CDV. During therapy all pertinent data elements were reviewed to characterize potential response to therapy and incidence of renal dysfunction. Results: Of the 19 CDV courses prescribed, 16 courses (84%) were in patients who had a positive blood ADV Polymerase chain reaction (PCR) alone or in combination with positive ADV PCR/ Direct Immunofluorescence Assay (DFA) at another site. Respiratory symptoms with or without pneumonia were the most common presentation (10/19, 53%). In the majority of blood positive courses (10/16, 63%), viral clearance was also accompanied by clinical response. This was not the case in four courses where patients expired despite viral clearance, including one in which death was directly attributable to adenovirus. There was reversible renal dysfunction observed during the use of CDV. Conclusions: CDV appeared safe and reasonably tolerated for treatment of ADV in this pediatric population and was associated with viral response and clinical improvement in the majority of patients but reversible renal dysfunction was a side effect. Further studies of the efficacy of CDV for immunocompromised children with ADV infection are warranted.",
        "contributors": [
            {
                "surname": "Ganapathi",
                "given-names": "Lakshmi"
            },
            {
                "surname": "Arnold",
                "given-names": "Alana"
            },
            {
                "surname": "Jones",
                "given-names": "Sarah"
            },
            {
                "surname": "Patterson",
                "given-names": "Al"
            },
            {
                "surname": "Graham",
                "given-names": "Dionne"
            },
            {
                "surname": "Harper",
                "given-names": "Marvin"
            },
            {
                "surname": "Levy",
                "given-names": "Ofer"
            }
        ],
        "url": "https://f1000research.com/articles/5-758/v2/",
        "doc_id": "5-758",
        "version": 2,
        "ix_counter": 314,
        "sentence_split_type": "HybridSplitterLessAndLong",
        "sentence_split_model": "HybridSplitterLessAndLong_SciSpacy+Spacy"
    }
}